US20210179721A1 - Method of treating or preventing ischemia-reperfusion injury - Google Patents

Method of treating or preventing ischemia-reperfusion injury Download PDF

Info

Publication number
US20210179721A1
US20210179721A1 US16/768,159 US201816768159A US2021179721A1 US 20210179721 A1 US20210179721 A1 US 20210179721A1 US 201816768159 A US201816768159 A US 201816768159A US 2021179721 A1 US2021179721 A1 US 2021179721A1
Authority
US
United States
Prior art keywords
compound
inhibits
protein
antibody
organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/768,159
Other languages
English (en)
Inventor
Ingela Vikstrom
Adriana BAZ MORELLI
Martin Pearse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017904822A external-priority patent/AU2017904822A0/en
Application filed by CSL Ltd filed Critical CSL Ltd
Assigned to CSL LIMITED reassignment CSL LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAZ MORELLI, Adriana, PEARSE, MARTIN, VIKSTROM, Ingela
Publication of US20210179721A1 publication Critical patent/US20210179721A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the present disclosure relates to methods of treating or preventing ischemia-reperfusion injury in a subject by antagonizing granulocyte-colony stimulating factor (G-CSF) signaling and uses thereof, e.g., in organ transplantation.
  • G-CSF granulocyte-colony stimulating factor
  • Ischemia-reperfusion injury is a pathological condition caused by ischemia, i.e. a restriction or reduction of the blood supply to a tissue or organ, for example, a deceased donor organ for transplantation, followed by subsequent reperfusion and re-oxygenation.
  • Ischemia causes deprivation of oxygen and nutrients to cells and inadequate removal of metabolic waste, and can rapidly lead to necrosis and inflammation.
  • Reperfusion of a tissue or organ after a period of ischemia returns the blood supply and oxygen, however the reperfusion itself can accentuate the oxidation and inflammation caused by the initial ischemia and cause further injury.
  • Reoxygenation can cause oxidative damage to cellular proteins, DNA and the plasma membrane. Such oxidative damage may in turn cause the release of free radicals resulting in further cellular damage.
  • Reperfusion injury is characterized by among other things, the generation of reactive oxygen species, complement activation, cellular inflammation and endothelial cell damage.
  • ischemia-reperfusion injury can be defined as ‘warm’ IRI or ‘cold’ IRI.
  • Warm IRI occurs in situ during organ transplantation surgery or during various forms of shock or trauma.
  • Cold IRI occurs during ex vivo preservation and is usually coupled with warm IRI during organ transplantation surgery.
  • ischemia-reperfusion injury Both the innate and adaptive immune systems have a central role in the pathogenesis of ischemia-reperfusion injury.
  • danger signals released by dying cells activate Toll-like receptors leading to activation and/or production of cellular and soluble factors that regulate inflammatory cell recruitment and the production of inflammatory mediators, e.g. chemokines, cytokines and free radicals.
  • chemokines e.g. chemokines, cytokines and free radicals.
  • Neutrophils are among the primary inflammatory cell responders following ischemia and reperfusion.
  • dendritic cells take up and process antigens from dying cells, migrate to the lymph nodes and activate antigen-specific cells of the adaptive immune system.
  • the pathogenesis of ischemia-reperfusion injury is complex and tissue damage likely occurs through several mechanisms such as cell death, microvascular dysfunction, transcriptional reprogramming, activation of complement and the innate and adaptive immune systems.
  • Ischemia-reperfusion injury is a frequent event in transplantation, including kidney transplantation, and is a relevant factor in determining both short-term and long-term graft outcome.
  • IRI affects endothelial cells and tubular epithelial cells and can cause acute kidney injury and delayed graft function (DGF), which can impair graft survival.
  • DGF is one of the more frequent early complications after deceased donor, or expanded-criteria donor kidney transplantation and is primarily caused by tubular epithelial cell necrosis caused by IRI (Schröppel B, et al., Kidney Int. 2014).
  • G-CSF Granulocyte-colony stimulating factor
  • G-CSF may have a protective role in ischemia-reperfusion injury and instead studied the effects of inhibiting G-CSF signaling on ischemia-reperfusion injury.
  • the inventors found that by administering a compound that inhibits G-CSF signaling, the effects of ischemia-reperfusion injury were reduced. Additionally, the inventors found that by inhibiting G-CSF signaling they could prevent or treat ischemia-reperfusion injury to a similar degree as inhibiting complement activation at the level of C5.
  • the present disclosure provides a method for preventing or treating ischemia-reperfusion injury in a subject, the method comprising administering a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling.
  • G-CSF granulocyte colony stimulating factor
  • the present disclosure also provides a compound that inhibits G-CSF signaling for use in the prevention or treatment of ischemia-reperfusion injury.
  • the present disclosure also provides use of a compound that inhibits G-CSF signaling in the manufacture of a medicament for the prevention or treatment of ischemia-reperfusion injury.
  • the ischemia and/or reperfusion injury is due to or associated with organ transplantation, cold organ storage, brain death, atherosclerosis, thrombosis, thromboembolism, lipid-embolism, trauma, bleeding, a stent, surgery, angioplasty, bypass surgery, total ischemia, myocardial infarction, stroke, peripheral vascular disease, sepsis, a tumor or combinations thereof.
  • the ischemia-reperfusion injury is warm ischemia-reperfusion injury. In some examples, the ischemia-reperfusion injury is cold ischemia-reperfusion injury.
  • the compound that inhibits G-CSF signaling is administered to the subject.
  • the ischemia-reperfusion injury is due to or associated with one or more of the following:
  • the ischemia-reperfusion injury is due to or associated with surgery.
  • the ischemia-reperfusion injury is due to or associated with coronary artery bypass surgery, e.g., a double bypass (in which two coronary arteries are bypassed (e.g., the left anterior descending coronary artery (LAD) and right coronary artery (RCA)); a triple bypass (in which three vessels are bypassed e.g., LAD, RCA and left circumflex artery (LCX)); a quadruple bypass (in which four vessels are bypassed (e.g., LAD, RCA, LCX and first diagonal artery of the LAD)); or a quintuple bypass (in which five arteries are bypassed).
  • a double bypass in which two coronary arteries are bypassed
  • RCA right coronary artery
  • LCX left circumflex artery
  • quadruple bypass in which four vessels are bypassed (e.g., LAD, RCA, LC
  • the ischemia-reperfusion injury is due to or associated with organ transplantation, e.g., a solid organ transplantation.
  • organ transplantation e.g., a solid organ transplantation.
  • the organ transplantation is a kidney transplantation.
  • the organ transplantation is a liver transplantation.
  • the organ transplantation is a heart transplantation.
  • the organ transplantation is a pancreas transplantation.
  • the organ transplantation is a lung transplantation.
  • the organ transplantation is a stomach transplantation.
  • the organ transplantation is an intestine transplantation.
  • the organ transplantation is a testis transplantation.
  • the organ transplantation is a skin transplantation, e.g., a full thickness skin transplantation.
  • the ischemia-reperfusion injury is due to or associated with a tissue transplantation.
  • the tissue transplantation is a blood vessel transplantation.
  • the tissue transplantation is a skin transplantation, for example vascularized skin.
  • the tissue transplantation is a pancreatic islet transplantation.
  • the tissue transplantation is a corneal transplantation.
  • the tissue transplantation is a musculoskeletal transplantation.
  • the compound that inhibits G-CSF signaling can be administered before, during and/or after transplantation.
  • the compound that inhibits G-CSF signaling is administered to the subject, wherein the subject is a tissue or organ transplantation recipient.
  • the compound that inhibits G-CSF signaling is administered to a tissue or organ transplantation donor.
  • the tissue or organ transplantation donor is a living donor. In some examples, the tissue or organ transplantation donor is a deceased donor. In some examples, the tissue or organ transplantation donor is a donation after brain death (DBD) donor. In some examples, the tissue or organ transplantation donor is a donation after circulatory death (DCD) donor. In some examples, the tissue or organ transplantation donor is an expanded-criteria donor (ECD). In some examples, the tissue or organ transplantation donor is a standard-criteria donor (SCD).
  • the compound that inhibits G-CSF signaling is administered to a harvested organ ex vivo, prior to organ transplantation.
  • the harvested organ can be perfused or infused with a solution comprising the compound that inhibits G-CSF signaling prior to transplantation.
  • the present disclosure also provides a method of tissue or organ transplantation or for improving outcome of a tissue or organ transplantation or improving function of a transplanted tissue or organ or for preventing delayed graft function, the method comprising administering a compound that inhibits G-CSF signaling to a harvested tissue or organ ex vivo and transplanting the harvested tissue or organ into a tissue or organ transplant recipient.
  • the compound that inhibits G-CSF signaling is administered to the organ transplantation donor and/or the organ transplantation recipient and/or the harvested organ. In some examples, the compound that inhibits G-CSF signaling is administered to the organ transplantation donor and the organ transplantation recipient.
  • the compound that inhibits G-CSF signaling is administered to the organ transplantation donor and the harvested organ. In some examples, the compound that inhibits G-CSF signaling is administered to the organ transplantation recipient and the harvested organ.
  • the compound that inhibits G-CSF signaling is administered before reperfusion, for example, in the case of a transplant (e.g., organ transplant), the compound that inhibits G-CSF signaling is administered to an organ transplant recipient prior to reperfusion of the transplanted organ (e.g., the compound. that inhibits G-CSF signaling is administered prior to the transplantation or during the transplantation but before reperfusion, e.g., before clamps restricting the flow of blood are released).
  • a transplant e.g., organ transplant
  • the compound that inhibits G-CSF signaling is administered prior to the transplantation or during the transplantation but before reperfusion, e.g., before clamps restricting the flow of blood are released.
  • the compound that inhibits G-CSF signaling is administered before ischemia.
  • the compound that inhibits G-CSF signaling is administered between between 0 days (e.g., immediately prior to either ischemia or reperfusion) to 7 days before ischemia or reperfusion.
  • the compound that inhibits G-CSF signaling is administered between 0 days and 6 days or 5 days or 4 days before reperfusion or ischemia.
  • the compound that inhibits G-CSF signaling is administered between 0 and 72 hours before reperfusion or ischemia.
  • the compound that inhibits G-CSF signaling is administered between 6 and 48 hours before reperfusion or ischemia.
  • the compound that inhibits G-CSF signaling is administered between 12 and 36 hours before reperfusion or ischemia.
  • the compound that inhibits G-CSF signaling is administered about 24 hours before reperfusion or ischemia.
  • the compound that inhibits G-CSF signaling is administered at least 1 hour before reperfusion or ischemia (and up to 7 days before reperfusion or ischemia). In some examples, the compound that inhibits G-CSF signaling is administered at least 2 or at least 4 or at least 6 or at least 8 or at least 10 or at least 12 hours or at least 14 hours or at least 16 hours or at least 18 hours or at least 20 hours or at least 22 hours or at least 24 hours before reperfusion or ischemia. In some examples, the compound that inhibits G-CSF signaling is administered at least 24 hours before reperfusion or ischemia.
  • the discussion shall relate to multiple administrations of the compound.
  • the present disclosure encompasses multiple administrations of the compound (e.g., 2 or 3 or 4 or 5 etc.) between 0 days and 7 days before ischemia or reperfusion.
  • the compound in the case of a transplant, can be administered multiple times following transplantation.
  • the present disclosure provides a method of transplantation (e.g., organ transplantation) or for improving outcome of transplantation (e.g., organ transplantation) or improving function of a transplant (e.g., a transplanted organ) or for preventing delayed graft function, the method comprising administering a compound that inhibits G-CSF signaling to a transplant donor prior to collection of tissue or an organ; collecting the transplant (e.g., tissue/organ) and transplanting the tissue or organ into an organ transplant recipient.
  • a method of transplantation e.g., organ transplantation
  • for improving outcome of transplantation e.g., organ transplantation
  • improving function of a transplant e.g., a transplanted organ
  • the method comprising administering a compound that inhibits G-CSF signaling to a transplant donor prior to collection of tissue or an organ; collecting the transplant (e.g., tissue/organ) and transplanting the tissue or organ into an organ transplant recipient.
  • the present disclosure also provides a method for preparing a transplant tissue or organ from a tissue or organ donor to improve tissue or organ function in a tissue or organ transplant recipient, the method comprising administering to the tissue or organ donor a compound that inhibits G-CSF signaling prior to collection of the tissue or organ.
  • the present disclosure additionally provides a method for preventing tissue or organ transplant rejection, the method comprising administering to a tissue or organ donor a compound that inhibits G-CSF signaling prior to collection of the tissue or organ, collecting the tissue or organ and transplanting the tissue or organ into a tissue or organ transplant recipient.
  • the method additionally comprises administering the compound that inhibits G-CSF signaling to the transplant recipient.
  • the compound that inhibits G-CSF signaling is administered to the transplant recipient before the transplant or at or around the time of transplanting the tissue or organ.
  • the compound that inhibits G-CSF signaling is administered to the transplant recipient during tissue or organ transplantation surgery.
  • the present disclosure also provides a method of organ transplantation or for improving outcome of a tissue or organ transplantation or improving function of a transplanted tissue or organ or for preventing delayed graft function, the method comprising administering a compound that inhibits G-CSF signaling to a transplant recipient prior to transplanting the tissue or organ and then transplanting the organ into the transplant recipient.
  • the organ transplant donor is brain dead.
  • the organ donor is alive and on life support but is brain dead. Additional donors are described herein and taken to apply to this example of the disclosure.
  • the compound that inhibits G-CSF signaling can be administered before the organ is collected, e.g., between 0 and 72 hours before organ collection. In one example, the compound that inhibits G-CSF signaling is administered between 6 and 48 hours before organ collection. In one example, the compound that inhibits G-CSF signaling is administered between 12 and 36 hours before organ collection. In one example, the compound that inhibits G-CSF signaling is administered about 24 hours before organ collection.
  • the compound that inhibits G-CSF signaling can be administered at a time between brain death and organ collection.
  • the compound that inhibits G-CSF signaling can be administered is administered within 48 hours of brain death being declared, e.g., within 24 hours or 12 hours or 6 hours of brain death being declared.
  • the compound that inhibits G-CSF signaling is administered as a single dose.
  • the compound that inhibits G-CSF signaling is administered in a plurality of doses.
  • the compound is administered to a transplant recipient prior to transplantation or during transplantation and then one or more additional doses is(are) administered to the recipient following transplantation.
  • the compound that inhibits G-CSF signaling is administered to a transplant donor or a donated tissue or organ and then one or more additional doses is(are) administered to a transplant recipient following transplantation.
  • the compound that inhibits G-CSF signaling is administered in a prophylactically or therapeutically effective amount.
  • the compound that inhibits G-CSF signaling is administered at a dose of between about 0.01 mg/kg to about 50 mg/kg, such as between about 0.05 mg/kg to about 30 mg/kg, for example, between about 0.1 mg/kg to about 20 mg/kg, for example, between about 1 mg/kg to about 10 mg/kg.
  • the compound that inhibits G-CSF signaling is administered at a dose of between about 0.1 mg/kg to about 1 mg/kg.
  • the compound that inhibits G-CSF signaling is administered at a dose of between about 0.4 mg/kg to about 0.5 mg/kg.
  • the compound that inhibits G-CSF signaling is administered at a dose of about 0.1 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.2 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.3 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.4 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.5 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.6 mg/kg.
  • the compound that inhibits G-CSF signaling is administered at a dose of about 0.7 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.8 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 1 mg/kg. In some examples, the compound that inhibits G-CSF signaling is administered at a dose of between about 2 mg/kg to about 8 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of between about 4 mg/kg to about 6 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 5 mg/kg.
  • the compound that inhibits G-CSF signaling is administered in an amount that causes neutropenia.
  • the compound that inhibits G-CSF signaling is administered in an amount that causes transient neutropenia, e.g., for a period of less than one week or less than 5 days or less than 3 days or less than 1 day.
  • the compound that inhibits G-CSF signaling is administered in an amount that does not cause neutropenia.
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent inflammation. In one example, the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent oxidative damage.
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to have one or more of the following effects:
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent neutrophil infiltration. In one example, the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent macrophage infiltration. In one example, the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or inhibit expression of interleukin 8 receptor beta (IL-8R ⁇ ). In one example, the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or inhibit expression of monocyte chemoattractant protein 1 (MCP-1).
  • MCP-1 monocyte chemoattractant protein 1
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to have one or more of the following effects:
  • Serum or plasma creatinine levels and serum or plasma urea levels are measures of kidney function and are useful in assessing delayed graft function, e.g., in the case of a kidney transplantation, as described herein.
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent an increase in serum or plasma creatinine levels. In one example, the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent an increase in serum or plasma urea levels.
  • Increased levels of albumin and/or blood in urine can also indicate impaired kidney function or kidney damage.
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent an increase in urine albumin levels.
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent an increase in levels of blood in the subject's urine.
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or inhibit expression of one or more of the following, e.g. by cells of the transplanted organ in the case of an organ transplantation:
  • kidney injury molecule 1 KIM-1
  • neutrophil gelatinase-associated lipocalin (ii) neutrophil gelatinase-associated lipocalin (NGAL);
  • TNF ⁇ tumor necrosis factor alpha
  • xii monocyte chemoattractant protein 1 (MCP-1).
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent complement C5 activation.
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent C5b-9 deposition, e.g. on the surface of cells of the transplanted organ in the case of an organ transplantation.
  • the compound that inhibits G-CSF signaling is administered in combination with another compound.
  • the other compound is hydrogen sulfide.
  • the other compound is an anti-inflammatory compound and/or specifically inhibits or reduces the expression or activity of one or more of the molecules listed at (i)-(x) above.
  • the other compound is an immunosuppressant, e.g. cyclosporine. Suitable immunosuppressants will be known in the art and include those described in James & Mannon, Curr Transplant Rep (2015), which is incorporated herein by reference.
  • the other compound is a corticosteroid, such as prednisone and/or prednisolone.
  • the other compound is methotrexate.
  • the other compound is cyclophosphamide.
  • the other compound is mycophenolate mofetil.
  • the other compound is TR040303, as described in Le Lamer et al., J Transl Med (2014).
  • the other compound is superoxide dismutase.
  • the other compound is metformin.
  • the other compound is a cannabinoid or a synthetic analog thereof.
  • the other compound is one that is commonly used in transplantation surgery.
  • the compound that inhibits G-CSF signaling is administered in combination with a cell.
  • the cell is a stem cell, such as a mesenchymal stem cell.
  • the compound that inhibits G-CSF signaling is administered in combination with a gene therapy.
  • the compound that inhibits G-CSF signaling is administered simultaneously with the other compound. In one example, the compound that inhibits G-CSF signaling is administered before the other compound. In one example, the compound that inhibits G-CSF signaling is administered after the other compound.
  • both the compound that inhibits G-CSF signaling and the other compound are administered to an organ transplant recipient.
  • Suitable other compounds are described above.
  • the compound that inhibits G-CSF signaling is administered to an organ transplant donor prior to collection of an organ for transplant and the other compound is administered to the organ transplant recipient, optionally in combination with the compound that inhibits G-CSF signaling.
  • Suitable other compounds are described above.
  • the compound that inhibits G-CSF signaling binds to G-CSF or to G-CSF receptor (G-CSFR). In one example, the compound that inhibits G-CSF signaling binds to G-CSF. In one example, the compound that inhibits G-CSF signaling binds to G-CSF receptor (G-CSFR).
  • the compound that inhibits G-CSF signaling is a protein.
  • the compound that inhibits G-CSF signaling is a protein comprising an antibody variable region that binds to or specifically binds to G-CSFR and neutralizes G-CSF signaling.
  • Reference herein to a protein or antibody that “binds to” G-CSFR provides literal support for a protein or antibody that “binds specifically to” G-CSFR.
  • the compound that inhibits G-CSF signaling is a protein comprising an antibody variable region that binds to or specifically binds to G-CSF and neutralizes G-CSF signaling.
  • Reference herein to a protein or antibody that “binds to” G-CSF provides literal support for a protein or antibody that “binds specifically to” G-CSF.
  • the compound that inhibits G-CSF signaling is a protein comprising a Fv.
  • the protein is selected from the group consisting of:
  • (x) one of (i) to (ix) linked to a constant region of an antibody, Fc or a heavy chain constant domain (C H ) 2 and/or C H 3;
  • (xi) one of (i) to (ix) linked to albumin, functional fragments or variants thereof or a protein (e.g., antibody or antigen binding fragment thereof) that binds to albumin; or
  • the protein is an antibody.
  • the antibody is a naked antibody. Exemplary antibodies are described in WO2012171057, which is incorporated herein by reference.
  • the protein is an antibody which binds to hG-CSFR expressed on the surface of a cell at an affinity of at least about 5 nM. In one example, the protein is an antibody which binds to hG-CSFR expressed on the surface of a cell at an affinity of at least about 4 nM. In one example, the protein is an antibody which binds to hG-CSFR expressed on the surface of a cell at an affinity of at least about 3 nM. In one example, the protein is an antibody which binds to hG-CSFR expressed on the surface of a cell at an affinity of at least about 2 nM. In one example, the protein is an antibody which binds to hG-CSFR expressed on the surface of a cell at an affinity of at least about 1 nM.
  • the protein is an antibody which inhibits G-CSF-induced proliferation of a BaF3 cell expressing hG-CSFR with an IC50 of at least about 5 nM. In one example, the protein is an antibody which inhibits G-CSF-induced proliferation of a BaF3 cell expressing hG-CSFR with an IC50 of at least about 4 nM. In one example, the protein is an antibody which inhibits G-CSF-induced proliferation of a BaF3 cell expressing hG-CSFR with an IC50 of at least about 3 nM. In one example, the protein is an antibody which inhibits G-CSF-induced proliferation of a BaF3 cell expressing hG-CSFR with an IC50 of at least about 2 nM.
  • the protein is an antibody which inhibits G-CSF-induced proliferation of a BaF3 cell expressing hG-CSFR with an IC50 of at least about 1 nM. In one example, the protein is an antibody which inhibits G-CSF-induced proliferation of a BaF3 cell expressing hG-CSFR with an IC50 of at least about 0.5 nM.
  • the protein is chimeric, de-immunized, humanized, human or primatized. In one example, the protein or antibody is human.
  • the protein comprises an antibody variable region that competitively inhibits the binding of antibody C1.2G comprising a heavy chain variable region (V H ) comprising a sequence set forth in SEQ ID NO: 4 and a light chain variable region (V L ) comprising a sequence set forth in SEQ ID NO: 5 to G-CSFR.
  • V H heavy chain variable region
  • V L light chain variable region
  • the protein binds to an epitope comprising residues within one or two or three or four regions selected from 111-115, 170-176, 218-234 and/or 286-300 of SEQ ID NO: 1.
  • the protein is an antibody comprising a heavy chain variable region (VH) comprising an amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region (VL) comprising an amino acid sequence set forth in SEQ ID NO: 5.
  • VH heavy chain variable region
  • VL light chain variable region
  • the protein is an antibody comprising a VH comprising an amino acid sequence set forth in SEQ ID NO: 2 and a VL comprising an amino acid sequence set forth in SEQ ID NO: 3.
  • the protein is an antibody comprising a VH comprising three CDRs of a VH comprising an amino acid sequence set forth in SEQ ID NO: 4 and a VL comprising three CDRs of a VL comprising an amino acid sequence set forth in SEQ ID NO: 5.
  • the protein is an antibody comprising a VH comprising three CDRs of a VH comprising an amino acid sequence set forth in SEQ ID NO: 2 and a VL comprising three CDRs of a VL comprising an amino acid sequence set forth in SEQ ID NO: 3.
  • the protein is an antibody comprising:
  • FIG. 1 is a graphical representation of serum creatinine concentrations 24 hours post reperfusion in the renal warm ischemia-reperfusion injury model.
  • FIG. 2 is a graphical representation of plasma urea concentrations 24 hours post reperfusion in the renal warm ischemia-reperfusion injury model.
  • Unpaired T-test *p ⁇ 0.05 (n 8 mice per group). The results are representative of two independent experiments—see also FIG. 8 .
  • FIG. 3 is a graphical representation of neutrophil count per high power field (HPF) in renal tissue.
  • HPF high power field
  • FIG. 4 is a graphical representation of macrophage count per high power field (HPF) in renal tissue.
  • HPF high power field
  • FIG. 5 is a graphical representation of (A) neutrophil and (B) macrophage count per high power field (HPF) in renal tissue.
  • FIG. 7 is a graphical representation of KIM-1, NGAL, IL-6, IL-8R ⁇ /CXCR2, MCP-1/CCL2, CXCL1, MIP-2/CXCL2, ICAM-1, and C5aR mRNA expression in renal tissue in the warm renal IRI model as assessed by qRT-PCR.
  • VR81 treatment at a dosage of 500 ⁇ g/mouse significantly reduced expression of (A) KIM-1, NGAL, IL-6, IL-8R ⁇ /CXCR2, MCP-1/CCL2, CXCL1, and (B) MIP-2/CXCL2, ICAM-1, and C5aR compared to treatment with the isotype control antibody.
  • FIG. 8 is a graphical representation of the percent frequency of neutrophils (CD11b + Gr1 + ) in the warm renal IRI model as assessed by flow cytometry in (A) kidney and (B) peripheral blood of mice treated with 100 ⁇ g of the anti-G-CSFR antibody VR81 or 100 ⁇ g of an anti-C5 antibody (BB5.1) compared to mice treated with 100 ⁇ g of an isotype control antibody and sham mice.
  • Significantly lower levels of neutrophils (CD11b + Gr1 + ) were observed in the kidneys of sham mice and mice treated with VR81 or BB5.1 compared to the levels observed in mice treated with an isotype control antibody.
  • Neutrophil populations in the blood were similar in all groups and unaffected by the treatments.
  • FIG. 9 is a graphical representation of serum creatinine concentrations in the warm renal IRI model.
  • Treatment with 100 ⁇ g of the anti-G-CSFR antibody VR81 or 100 ⁇ g of the anti-C5 antibody BB5.1 significantly reduced creatinine concentrations compared to treatment of mice with 100 ⁇ g of an isotype control antibody.
  • the reductions seen with the VR81 and with BB5.1 were not significantly different.
  • One-Way ANOVA Kruskal-Wallis test, Dunn's Multiple Comparison Test, *p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.005 (n 7-8 mice per group).
  • FIG. 10 is a graphical representation of plasma urea concentrations in the warm renal IRI model.
  • Treatment with 100 ⁇ g of the anti-G-CSFR antibody VR81 or 100 ⁇ g of the anti-C5 antibody BB5.1 significantly reduced plasma urea concentrations compared to treatment of mice with 100 ⁇ g of an isotype control antibody. The reductions seen with VR81 and with BB5.1 were not significantly different.
  • One-Way ANOVA Kruskal-Wallis test, Dunn's Multiple Comparison Test, *p ⁇ 0.05, **p ⁇ 0.01 (n 7-8 mice per group).
  • FIG. 11 is a graphical representation of serum urea concentrations in the warm renal IRI model.
  • One-Way ANOVA Kruskal-Wallis test, Dunn's Multiple Comparison Test *p ⁇ 0.05, **p ⁇ 0.01 (n 6-8 mice per group).
  • FIG. 13 is a graphical representation of the percent frequency of neutrophils (CD11b + Gr1 + Ly6G + ) in (A) blood and (B) kidney in the warm renal IRI model.
  • FIG. 14 is a graphical representation of plasma C5a (A) and kidney C5b-9 deposition (B).
  • FIG. 15 is a graphical representation of the frequency of neutrophils (CD11b + Gr1 + Ly6G + ) in blood and kidney in the warm renal IRI model.
  • composition of matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of matter, groups of steps or groups of compositions of matter.
  • variable regions and parts thereof, immunoglobulins, antibodies and fragments thereof herein may be further clarified by the discussion in Kabat Sequences of Proteins of Immunological Interest , National Institutes of Health, Bethesda, Md., 1987 and 1991, Bork et al., J Mol. Biol. 242, 309-320, 1994, Chothia and Lesk J. Mol Biol. 196:901-917, 1987, Chothia et al. Nature 342, 877-883, 1989 and/or or Al-Lazikani et al., J Mol Biol 273, 927-948, 1997.
  • derived from shall be taken to indicate that a specified integer may be obtained from a particular source albeit not necessarily directly from that source.
  • a “compound”, as contemplated by the present disclosure, can take any of a variety of forms including natural compounds, chemical small molecule compounds or biological compounds or macromolecules.
  • Exemplary compounds include an antibody or an antigen binding fragment of an antibody, a nucleic acid, a polypeptide, a peptide, and a small molecule.
  • G-CSF granulocyte colony-stimulating factor
  • mutant forms thereof e.g., filgrastim and pegylated forms of G-CSF or filgrastim.
  • This term also encompasses mutant forms of G-CSF retaining activity to bind to G-CSFR (e.g., human G-CSFR) and induce signaling.
  • G-CSF is a major regulator of granulocyte production.
  • G-CSF is produced by bone marrow stromal cells, endothelial cells, macrophages, and fibroblasts, and production is induced by inflammatory stimuli.
  • G-CSF acts through the G-CSF receptor (G-CSFR), which is expressed on early myeloid progenitors, mature neutrophils, monocytes/macrophages, T and B lymphocytes and endothelial cells.
  • G-CSFR G-CSF receptor
  • an exemplary sequence of a human G-CSFR is set out in NCBI Reference Sequence: NP_000751.1 (and set out in SEQ ID NO: 16).
  • the sequence of G-CSFR from other species can be determined using sequences provided herein and/or in publically available databases and/or determined using standard techniques (e.g., as described in Ausubel et al., (editors), Current Protocols in Molecular Biology, Greene Pub.
  • G-CSFR may be abbreviated to hG-CSFR and reference to cynomolgus monkey G-CSFR may be abbreviated to cynoG-CSFR.
  • Reference to soluble G-CSFR refers to polypeptides comprising the ligand binding region of G-CSFR. The Ig and CRH domains of the G-CSFR are involved in ligand binding and receptor dimerization (Layton et al., J.
  • ischemia-reperfusion injury refers to tissue or organ damage caused when blood supply returns to the tissue or organ after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than restoration of normal function.
  • Ischemia-reperfusion injury IRI is also known as “reperfusion injury”, “reperfusion insult”, and “reoxygenation injury”.
  • ischemia-reperfusion injury includes both warm ischemia-reperfusion injury and cold ischemia-reperfusion injury.
  • ischemia also known as “ischaemia” refers to a restriction in blood supply to tissues, causing a shortage of oxygen and glucose needed for cellular metabolism, as well as causing a buildup and reduced removal of metabolic waste.
  • fusion relates to the restoration of blood flow or oxygen to the tissue.
  • condition refers to a disruption of or interference with normal function, and is not to be limited to any specific condition, and will include diseases or disorders.
  • the terms “preventing”, “prevent” or “prevention” include administering a compound of the disclosure to thereby stop or hinder, at least partially, the development of at least one symptom of a condition. This term also encompasses treatment of a subject in remission to prevent or hinder relapse.
  • treating include administering a compound described herein to thereby reduce or eliminate at least one symptom of a specified disease or condition.
  • the term “neutropenia” is used to refer to an absolute neutrophil count (ANC) below the lower limit of normal range, for example an ANC of less than 2000 cells/ ⁇ L blood, or less than 1500 cells/ ⁇ L blood, or less than 1000 cells/ ⁇ L blood, for example less than 500 cells/ ⁇ L blood (see Sibille et al. 2010 Br J Clin Pharmacol 70(5): 736-748).
  • the compound that inhibits G-CSF signaling is administered in an amount that does not cause severe neutropenia.
  • severe neutropenia is used to refer to an absolute neutrophil count (ANC) of less than 1000 cells/ ⁇ L blood.
  • the term “subject” shall be taken to mean any animal including humans, for example a mammal. Exemplary subjects include but are not limited to humans and non-human primates. For example, the subject is a human.
  • a donor e.g., an organ donor
  • a recipient e.g., an organ recipient
  • mammals for example humans.
  • protein shall be taken to include a single polypeptide chain, i.e., a series of contiguous amino acids linked by peptide bonds or a series of polypeptide chains covalently or non-covalently linked to one another (i.e., a polypeptide complex).
  • the series of polypeptide chains can be covalently linked using a suitable chemical or a disulphide bond.
  • non-covalent bonds include hydrogen bonds, ionic bonds, Van der Waals forces, and hydrophobic interactions.
  • polypeptide or “polypeptide chain” will be understood from the foregoing paragraph to mean a series of contiguous amino acids linked by peptide bonds.
  • isolated protein or “isolated polypeptide” is a protein or polypeptide that by virtue of its origin or source of derivation is not associated with naturally-associated components that accompany it in its native state; is substantially free of other proteins from the same source.
  • a protein may be rendered substantially free of naturally associated components or substantially purified by isolation, using protein purification techniques known in the art.
  • substantially purified is meant the protein is substantially free of contaminating agents, e.g., at least about 70% or 75% or 80% or 85% or 90% or 95% or 96% or 97% or 98% or 99% free of contaminating agents.
  • recombinant shall be understood to mean the product of artificial genetic recombination. Accordingly, in the context of a recombinant protein comprising an antibody antigen binding domain, this term does not encompass an antibody naturally-occurring within a subject's body that is the product of natural recombination that occurs during B cell maturation. However, if such an antibody is isolated, it is to be considered an isolated protein comprising an antibody antigen binding domain. Similarly, if nucleic acid encoding the protein is isolated and expressed using recombinant means, the resulting protein is a recombinant protein comprising an antibody antigen binding domain. A recombinant protein also encompasses a protein expressed by artificial recombinant means when it is within a cell, tissue or subject, e.g., in which it is expressed.
  • an antigen binding site shall be taken to mean a structure formed by a protein that is capable of binding or specifically binding to an antigen.
  • the antigen binding site need not be a series of contiguous amino acids, or even amino acids in a single polypeptide chain.
  • the antigen binding site is made up of a series of amino acids of a V L and a V H that interact with the antigen and that are generally, however not always in the one or more of the CDRs in each variable region.
  • an antigen binding site is a V H or a V L or a Fv.
  • an “antibody” is generally considered to be a protein that comprises a variable region made up of a plurality of polypeptide chains, e.g., a polypeptide comprising a V L and a polypeptide comprising a V H .
  • An antibody also generally comprises constant domains, some of which can be arranged into a constant region, which includes a constant fragment or fragment crystallizable (Fc), in the case of a heavy chain.
  • Fc constant fragment or fragment crystallizable
  • a light chain from mammals is either a ⁇ light chain or a ⁇ light chain and a heavy chain from mammals is ⁇ , ⁇ , ⁇ , ⁇ , or ⁇ .
  • Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 and IgA 2 ) or subclass.
  • the term “antibody” also encompasses humanized antibodies, primatized antibodies, human antibodies and chimeric antibodies.
  • full-length antibody “intact antibody” or “whole antibody” are used interchangeably to refer to an antibody in its substantially intact form, as opposed to an antigen binding fragment of an antibody.
  • whole antibodies include those with heavy and light chains including an Fc region.
  • the constant domains may be wild-type sequence constant domains (e.g., human wild-type sequence constant domains) or amino acid sequence variants thereof.
  • variable region refers to the portions of the light and/or heavy chains of an antibody as defined herein that is capable of specifically binding to an antigen and includes amino acid sequences of complementarity determining regions (CDRs); i.e., CDR1, CDR2, and CDR3, and framework regions (FRs).
  • CDRs complementarity determining regions
  • FRs framework regions
  • Exemplary variable regions comprise three or four FRs (e.g., FR1, FR2, FR3 and optionally FR4) together with three CDRs.
  • the protein may lack a CDR2.
  • V H refers to the variable region of the heavy chain.
  • V L refers to the variable region of the light chain.
  • CDRs complementarity determining regions
  • CDR1, CDR2, and CDR3 refers to the amino acid residues of an antibody variable region the presence of which are necessary for antigen binding.
  • Each variable region typically has three CDR regions identified as CDR1, CDR2 and CDR3.
  • the amino acid positions assigned to CDRs and FRs can be defined according to Kabat Sequences of Proteins of Immunological Interest , National Institutes of Health, Bethesda, Md., 1987 and 1991 or other numbering systems in the performance of this disclosure, e.g., the canonical numbering system of Chothia and Lesk J. Mol Biol.
  • V H framework regions (FRs) and CDRs are positioned as follows: residues 1-30 (FR1), 31-35 (CDR1), 36-49 (FR2), 50-65 (CDR2), 66-94 (FR3), 95-102 (CDR3) and 103-113 (FR4).
  • V L FRs and CDRs are positioned as follows: residues 1-23 (FR1), 24-34 (CDR1), 35-49 (FR2), 50-56 (CDR2), 57-88 (FR3), 89-97 (CDR3) and 98-107 (FR4).
  • the present disclosure is not limited to FRs and CDRs as defined by the Kabat numbering system, but includes all numbering systems, including those discussed above.
  • reference herein to a CDR (or a FR) is in respect of those regions according to the Kabat numbering system.
  • FRs Framework regions
  • the term “Fv” shall be taken to mean any protein, whether comprised of multiple polypeptides or a single polypeptide, in which a V L and a V H associate and form a complex having an antigen binding site, i.e., capable of specifically binding to an antigen.
  • the V H and the V L which form the antigen binding site can be in a single polypeptide chain or in different polypeptide chains.
  • an Fv of the disclosure (as well as any protein of the disclosure) may have multiple antigen binding sites which may or may not bind the same antigen. This term shall be understood to encompass fragments directly derived from an antibody as well as proteins corresponding to such a fragment produced using recombinant means.
  • the V H is not linked to a heavy chain constant domain (C H ) 1 and/or the V L is not linked to a light chain constant domain (C L ).
  • exemplary Fv containing polypeptides or proteins include a Fab fragment, a Fab′ fragment, a F(ab′) fragment, a scFv, a diabody, a triabody, a tetrabody or higher order complex, or any of the foregoing linked to a constant region or domain thereof, e.g., C H 2 or C H 3 domain, e.g., a minibody.
  • a “Fab fragment” consists of a monovalent antigen-binding fragment of an immunoglobulin, and can be produced by digestion of a whole antibody with the enzyme papain, to yield a fragment consisting of an intact light chain and a portion of a heavy chain or can be produced using recombinant means.
  • a “Fab′ fragment” of an antibody can be obtained by treating a whole antibody with pepsin, followed by reduction, to yield a molecule consisting of an intact light chain and a portion of a heavy chain comprising a V H and a single constant domain. Two Fab′ fragments are obtained per antibody treated in this manner.
  • a Fab′ fragment can also be produced by recombinant means.
  • a “F(ab′)2 fragment” of an antibody consists of a dimer of two Fab′ fragments held together by two disulfide bonds, and is obtained by treating a whole antibody molecule with the enzyme pepsin, without subsequent reduction.
  • a “Fab 2 ” fragment is a recombinant fragment comprising two Fab fragments linked using, for example a leucine zipper or a C H 3 domain.
  • a “single chain Fv” or “scFv” is a recombinant molecule containing the variable region fragment (Fv) of an antibody in which the variable region of the light chain and the variable region of the heavy chain are covalently linked by a suitable, flexible polypeptide linker.
  • the term “binds” in reference to the interaction of a compound or an antigen binding site thereof with an antigen means that the interaction is dependent upon the presence of a particular structure (e.g., an antigenic determinant or epitope) on the antigen.
  • a particular structure e.g., an antigenic determinant or epitope
  • an antibody recognizes and binds to a specific protein structure rather than to proteins generally. If an antibody binds to epitope “A”, the presence of a molecule containing epitope “A” (or free, unlabeled “A”), in a reaction containing labeled “A” and the protein, will reduce the amount of labeled “A” bound to the antibody.
  • the term “specifically binds” or “binds specifically” shall be taken to mean that a compound of the disclosure reacts or associates more frequently, more rapidly, with greater duration and/or with greater affinity with a particular antigen or cell expressing same than it does with alternative antigens or cells.
  • a compound binds to G-CSFR (e.g., hG-CSFR) with materially greater affinity (e.g., 20 fold or 40 fold or 60 fold or 80 fold to 100 fold or 150 fold or 200 fold) than it does to other cytokine receptor or to antigens commonly recognized by polyreactive natural antibodies (i.e., by naturally occurring antibodies known to bind a variety of antigens naturally found in humans).
  • G-CSFR e.g., hG-CSFR
  • materially greater affinity e.g., 20 fold or 40 fold or 60 fold or 80 fold to 100 fold or 150 fold or 200 fold
  • polyreactive natural antibodies i.e., by naturally occurring antibodies known to bind a variety of antigens
  • a protein or antibody may be considered to “preferentially bind” to a polypeptide if it binds that polypeptide with a dissociation constant (K D ) that is less than the protein's or antibody's K D for another polypeptide.
  • K D dissociation constant
  • a protein or antibody is considered to preferentially bind to a polypeptide if it binds the polypeptide with an affinity (i.e., K D ) that is at least about 20 fold or 40 fold or 60 fold or 80 fold or 100 fold or 120 fold or 140 fold or 160 fold more than the protein's or antibody's K D for another polypeptide.
  • affinity in this specification is a reference to K D of a protein or antibody.
  • affinity of at least about will be understood to mean that the affinity (or K D ) is equal to the recited value or higher (i.e., the value recited as the affinity is lower), i.e., an affinity of 2 nM is greater than an affinity of 3 nM. Stated another way, this term could be “an affinity of X or less”, wherein X is a value recited herein.
  • an “IC 50 of at least about” will be understood to mean that the IC 50 is equal to the recited value or greater (i.e., the value recited as the IC 50 is lower), i.e., an IC 50 of 2 nM is greater than an IC 50 of 3 nM. Stated another way, this term could be “an IC 50 of X or less”, wherein X is a value recited herein.
  • epitope (syn. “antigenic determinant”) shall be understood to mean a region of hG-CSFR to which a protein comprising an antigen binding site of an antibody binds. This term is not necessarily limited to the specific residues or structure to which the protein makes contact. For example, this term includes the region spanning amino acids contacted by the protein and/or 5-10 or 2-5 or 1-3 amino acids outside of this region.
  • the epitope comprises a series of discontinuous amino acids that are positioned close to one another when hG-CSFR is folded, i.e., a “conformational epitope”.
  • a conformational epitope comprises amino acids in one or more or two or more or all of the regions corresponding to 111-115, 170-176, 218-234 and/or 286-300 of SEQ ID NO: 1.
  • epitope is not limited to peptides or polypeptides.
  • epipe includes chemically active surface groupings of molecules such as sugar side chains, phosphoryl side chains, or sulfonyl side chains, and, in certain examples, may have specific three dimensional structural characteristics, and/or specific charge characteristics.
  • a protein of the disclosure reduces or prevents binding of a recited antibody or protein to G-CSFR, e.g., to hG-CSFR. This may be due to the protein (or antigen binding site) and antibody binding to the same or an overlapping epitope. It will be apparent from the foregoing that the protein need not completely inhibit binding of the antibody, rather it need only reduce binding by a statistically significant amount, for example, by at least about 10% or 20% or 30% or 40% or 50% or 60% or 70% or 80% or 90% or 95%.
  • the protein reduces binding of the antibody by at least about 30%, more preferably by at least about 50%, more preferably, by at least about 70%, still more preferably by at least about 75%, even more preferably, by at least about 80% or 85% and even more preferably, by at least about 90%.
  • Methods for determining competitive inhibition of binding are known in the art and/or described herein.
  • the antibody is exposed to G-CSFR either in the presence or absence of the protein. If less antibody binds in the presence of the protein than in the absence of the protein, the protein is considered to competitively inhibit binding of the antibody. In one example, the competitive inhibition is not due to steric hindrance.
  • “Overlapping” in the context of two epitopes shall be taken to mean that two epitopes share a sufficient number of amino acid residues to permit a protein (or antigen binding site thereof) that binds to one epitope to competitively inhibit the binding of a protein (or antigen binding site) that binds to the other epitope.
  • the “overlapping” epitopes share at least 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 20 amino acids.
  • neutralize shall be taken to mean that a compound is capable of blocking, reducing or preventing G-CSF-mediated signaling in a cell through the G-CSFR. Methods for determining neutralization are known in the art and/or described herein.
  • the present disclosure provides, for example, a method for preventing or treating ischemia-reperfusion injury in a subject comprising administering a compound that inhibits granulocyte colony stimulating factor G-CSF signaling.
  • a compound that inhibits granulocyte colony stimulating factor G-CSF signaling for example, the compound binds to G-CSF or G-CSFR.
  • An ischemia-reperfusion injury can be caused by a natural event (e.g., restoration of blood flow following a myocardial infarction or stroke), a trauma, a tumor, or by one or more surgical procedures or other therapeutic interventions that restore blood flow or oxygen to a tissue or organ that has been subjected to a diminished supply of blood or oxygen.
  • a natural event e.g., restoration of blood flow following a myocardial infarction or stroke
  • a trauma e.g., a trauma, a tumor, or by one or more surgical procedures or other therapeutic interventions that restore blood flow or oxygen to a tissue or organ that has been subjected to a diminished supply of blood or oxygen.
  • the ischemia-reperfusion injury is caused by a surgical procedure.
  • surgical procedures include, for example, coronary artery bypass, graft surgery, coronary angioplasty, organ transplant surgery and the like (e.g., cardiopulmonary bypass surgery).
  • the ischemia and/or reperfusion injury is due to or associated with organ transplantation, cold organ storage, brain death, atherosclerosis, thrombosis, thromboembolism, lipid-embolism, trauma, bleeding, a stent, surgery, angioplasty, bypass surgery, total ischemia, myocardial infarction, stroke, peripheral vascular disease, surgery, sepsis, or combinations thereof.
  • the ischemia-reperfusion injury is due to or associated with organ transplantation.
  • the organ is a solid organ.
  • the organ transplantation is a kidney transplantation.
  • the organ transplantation is a liver transplantation.
  • the organ transplantation is a heart transplantation.
  • the organ transplantation is a pancreas transplantation.
  • the organ transplantation is a lung transplantation.
  • the organ transplantation is a stomach transplantation.
  • the organ transplantation is a intestine transplantation.
  • the organ transplantation is a testis transplantation.
  • the ischemia-reperfusion injury is due to or associated with a tissue transplantation.
  • the tissue transplantation is a blood vessel transplantation.
  • the tissue transplantation is a skin transplantation, for example vascularized skin.
  • the tissue transplantation is a pancreatic islet transplantation.
  • Effects of ischemia-reperfusion injury include organ dysfunction, infarct, inflammation, oxidative damage, mitochondrial membrane potential damage, apoptosis, reperfusion-related arrhythmia, cardiac stunning, cardiac lipotoxicity, ischemia-derived scar formation, and combinations thereof.
  • effects also include acute kidney injury and delayed graft function (DGF).
  • the method of the present disclosure prevents or reduces the likelihood of acute kidney injury following transplantation.
  • the method of the present disclosure prevents or reduces the risk of one or more of the following:
  • the method of the present disclosure prevents or reduces the likelihood of delayed graft function following transplantation, e.g., kidney transplantation.
  • delayed graft function is associated with poor long term graft outcomes, chronic graft rejection and/or organ survival.
  • the method of the present disclosure prevents or reduces the risk of one or more of the following:
  • the method of the present disclosure prevents or reduces the likelihood of one or more of the following:
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent inflammation, e.g., in a transplanted organ.
  • inflammation relates to a set of changes occurring in a tissue that undergoes inflammation.
  • inflammation relates to the biological response to harmful stimuli, including pathogens, damaged cells or irritants.
  • Methods to determine inflammation are known in the art and include, without limitation, measure of erythrocyte sedimentation rate (ESR), wherein a higher ESR is indicative of inflammation, measure of C-reactive protein (CRP), wherein a higher level of CRP is indicative of inflammation, and leukocyte count (increased in inflammation).
  • ESR erythrocyte sedimentation rate
  • CRP C-reactive protein
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent oxidative damage, e.g., in a transplanted organ.
  • oxidative damage relates to the biomolecular damage that can be caused by reactive species during oxygen restoration. Oxidative damage may involve lipid peroxidation, oxidative DNA damage and oxidative damage to proteins. Methods to determine lipid peroxidation include, without limitation, MDA (malondialdehyde)-TBA (thiobarbituric acid) determination by HPLC, and quantification of isoprostanes (which are specific end products of the peroxidation of polyunsaturated fatty acids) by mass spectrometry.
  • MDA malondialdehyde
  • TSA thiobarbituric acid
  • Methods to determine DNA oxidative damage include, without limitation, measure of 8-hydroxy-2′-deoxyguanosine (80HdG).
  • Methods to determine oxidative damage to proteins include, without limitation, quantification of individual aminoacid oxidation products including kynurenines (from tryptophan), bityrosine (which appears to be metabolically stable and can be detected in urine), valine and leucine hydroxides, L-dihydroxyphenylalanine (L-DOPA), ortho-tyrosine, 2-oxo-histidine, glutamate semialdehyde and adipic semialdehyde, as well as the carbonyl assay (involving measurement of protein carbonyl groups).
  • the mitochondrial membrane potential (Awl) relates to the membrane potential in the form of proton gradient across the mitochondrial inner membrane.
  • Methods for evaluation of mitochondrial membrane potential damage are known by the skilled person and include the use of fluorescent probes for monitoring membrane potential including the JC1 dye (Cell Technology) and the measure of overall fluorescence at excitation and emission wavelengths allowing the quantification of green (485 nm and 535 nm) and red fluorescence (550 nm and 600 nm).
  • JC1 dye Cell Technology
  • Prolonged ischemia of any tissue or organ is known to induce mitochondrial membrane potential damage.
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent neutrophil and/or macrophage infiltration.
  • neutrophil infiltration and “macrophage infiltration” refer to the recruitment or accumulation of neutrophils and macrophages in tissues or cells in response to a variety of substances being released at the sites of inflammatory reactions due to ischemia-reperfusion injury.
  • infiltration of neutrophils and/or macrophages can occur in donor organ tissue following organ transplantation. Methods of measuring neutrophil and/or macrophage infiltration will be known to those skilled in the art.
  • the neutrophils or macrophages can be measured directly, such as by visualisation by fluorescence microscopy, or indirectly by measuring the abundance or activity of neutrophil/macrophage specific proteins or enzymes in an affected tissue.
  • Suitable methods for measuring neutrophil and/or macrophage infiltration are described in Soo-Jeong Yu et al Korean J Intern Med (2008) and Pulli et al PloS One (2013).
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent complement C5 activation.
  • Methods for measuring complement C5a activation include, but are not limited to assessment of plasma C5a levels by enzyme-linked immunosorbent assay (ELISA).
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent C5b-9 deposition.
  • Methods for measuring C5b-9 deposition include, but are not limited to analysis by immunofluorescence staining of kidney sections.
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce expression of one or more of the following:
  • expression level of a gene can be measured by quantifying the amount of mRNA, e.g., by northern blot or by quantitative reverse transcription PCR (qRT-PCR) as described in Riedy et al Biotechniques (1995).
  • expression level of a gene can be measured by quantifying the level of protein encoded by the gene, e.g., by enzyme-linked immunosorbent assay (ELISA), fluorescence linked immunosorbent assay (FLISA), immunofluorescence or immunoblotting (see Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989)).
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent delayed graft function, for example, associated with kidney transplantation.
  • Delayed graft function is a manifestation of acute kidney injury resulting in post-transplantation oliguria, increased allograft immunogenicity and risk of acute rejection episodes, and decreased long-term survival.
  • Suitable biomarkers for detecting delayed graft function include NGAL, KIM-1, liver-type fatty acid binding protein (L-FABP), interleukin 18 (IL-18), YKL-40 (a 40 kDa heparin- and chitin-binding glycoprotein, see eg.
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent an increase in serum or plasma creatinine levels.
  • increased serum (or plasma) creatinine levels are an indicator of impaired kidney function. As a kidney becomes impaired for any reason, for example due to ischemia-reperfusion injury, the creatinine level in the blood will rise due to poor clearance of creatinine by the kidneys. Abnormally high levels of creatinine thus warn of possible malfunction or failure of the kidneys.
  • Suitable methods for measuring serum (or plasma) creatinine levels will be known in the art, for example the Jaffe reaction using alkaline picrate, and are described in Peake and Whiting, Clin Biochem Rev (2006).
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent an increase in serum or plasma urea levels.
  • Increased serum or plasma urea levels are an indicator of impaired kidney function, and can result from ischemia-reperfusion injury.
  • Serum or plasma urea can be measured by any suitable method known in the art.
  • serum or plasma urea can be measured by chemical methods such as the reaction of diacetyl (generated from diacetyl monoxime and acid) with urea to form diazine, or by enzymatic methods using e.g., urease to generate and measure ammonia or glutamate dehydrogenase, in which the consumption of NADH is measured.
  • the Cell Biolabs' Urea Assay Kit is based on the Berthelot reaction in which Urea is first degraded into ammonia and carbon dioxide, which further reacts with an alkaline developer to produce a blue-green coloured product that can be measured with a standard spectrophotometric plate reader at an optical density between 580-630 nm.
  • Suitable methods for measuring serum or plasma urea levels include those that are described in Lamb E et al., Kidney Function Tests (Chapter 25): Tietz Textbook of Clinical Chemistry and Molecular Diagnostics (2012).
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent an increase in urine albumin levels.
  • Increased urine albumin levels are an indicator of impaired kidney function, and can result from ischemia-reperfusion injury.
  • Urine albumin levels can be measured by any suitable method known in the art. For example, urine albumin levels can be measured using a microalbuminuria test.
  • the compound that inhibits G-CSF signaling is administered in an amount sufficient to reduce or prevent an increase in levels of blood in the subject's urine.
  • the presence of blood in urine also known as “haematuria” is an indicator of impaired kidney function, and can result from ischemia-reperfusion injury.
  • Levels of blood in the subject's urine can be measured by any suitable method known in the art. For example levels of blood in the subject's urine can be measured using a urine dipstick, or by detecting the presence of red blood cells by microscopic examination of a urine sample.
  • a compound as described herein according to any example is a protein comprising an antigen binding site of an antibody.
  • the compound that inhibits G-CSF signaling is an antibody.
  • the antibody binds to G-CSFR. In some examples, the antibody binds to G-CSF.
  • G-CSFR or G-CSF e.g., hG-CSFR or hG-CSF
  • a region thereof e.g., an extracellular domain
  • immunogenic fragment or epitope thereof or a cell expressing and displaying same i.e., an immunogen
  • an immunogen optionally formulated with any suitable or desired carrier, adjuvant, or pharmaceutically acceptable excipient, is administered to a non-human animal, for example, a mouse, chicken, rat, rabbit, guinea pig, dog, horse, cow, goat or pig.
  • the immunogen may be administered intranasally, intramuscularly, sub-cutaneously, intravenously, intradermally, intraperitoneally, or by other known route.
  • Monoclonal antibodies are one exemplary form of an antibody contemplated by the present disclosure.
  • the term “monoclonal antibody” or “mAb” refers to a homogeneous antibody population capable of binding to the same antigen(s), for example, to the same epitope within the antigen. This term is not intended to be limited as regards to the source of the antibody or the manner in which it is made.
  • mAbs For the production of mAbs any one of a number of known techniques may be used, such as, for example, the procedure exemplified in U.S. Pat. No. 4,196,265 or Harlow and Lane (1988), supra.
  • ABL-MYC technology (NeoClone, Madison Wis. 53713, USA) is used to produce cell lines secreting MAbs (e.g., as described in Largaespada et al, J. Immunol. Methods. 197: 85-95, 1996).
  • Antibodies can also be produced or isolated by screening a display library, e.g., a phage display library, e.g., as described in U.S. Pat. No. 6,300,064 and/or U.S. Pat. No. 5,885,793.
  • a display library e.g., a phage display library, e.g., as described in U.S. Pat. No. 6,300,064 and/or U.S. Pat. No. 5,885,793.
  • the present inventors have isolated fully human antibodies from a phage display library.
  • the antibody of the present disclosure may be a synthetic antibody.
  • the antibody is a chimeric antibody, a humanized antibody, a human antibody or a de-immunized antibody.
  • an antibody described herein is a chimeric antibody.
  • the term “chimeric antibody” refers to antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species (e.g., murine, such as mouse) or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species (e.g., primate, such as human) or belonging to another antibody class or subclass.
  • Methods for producing chimeric antibodies are described in, e.g., U.S. Pat. Nos. 4,816,567; and 5,807,715.
  • the antibodies of the present disclosure may be humanized or human.
  • humanized antibody shall be understood to refer to a subclass of chimeric antibodies having an antigen binding site or variable region derived from an antibody from a non-human species and the remaining antibody structure based upon the structure and/or sequence of a human antibody.
  • the antigen-binding site generally comprises the complementarity determining regions (CDRs) from the non-human antibody grafted onto appropriate FRs in the variable regions of a human antibody and the remaining regions from a human antibody.
  • Antigen binding sites may be wild-type (i.e., identical to those of the non-human antibody) or modified by one or more amino acid substitutions. In some instances, FR residues of the human antibody are replaced by corresponding non-human residues.
  • human antibody refers to antibodies having variable regions (e.g. V H , V L ) and, optionally constant regions derived from or corresponding to sequences found in humans, e.g. in the human germline or somatic cells.
  • Exemplary human antibodies are described herein and include C1.2 and C1.2G and/or variable regions thereof. These human antibodies provide an advantage of reduced immunogenicity in a human compared to non-human antibodies. Exemplary antibodies are described in WO2012171057, which is incorporated herein by reference.
  • a compound of the disclosure is a protein that is or comprises a single-domain antibody (which is used interchangeably with the term “domain antibody” or “dAb”).
  • a single-domain antibody is a single polypeptide chain comprising all or a portion of the heavy chain variable region of an antibody.
  • a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, Mass.; see, e.g., U.S. Pat. No. 6,248,516).
  • a protein of the disclosure is or comprises a diabody, triabody, tetrabody or higher order protein complex such as those described in WO98/044001 and/or WO94/007921.
  • scFvs comprise V H and V L regions in a single polypeptide chain and a polypeptide linker between the V H and V L which enables the scFv to form the desired structure for antigen binding (i.e., for the V H and V L of the single polypeptide chain to associate with one another to form a Fv).
  • the linker comprises in excess of 12 amino acid residues with (Gly4Ser) 3 being one of the more favored linkers for a scFv.
  • Heavy chain antibodies differ structurally from many other forms of antibodies, in so far as they comprise a heavy chain, but do not comprise a light chain. Accordingly, these antibodies are also referred to as “heavy chain only antibodies”. Heavy chain antibodies are found in, for example, camelids and cartilaginous fish (also called IgNAR).
  • the present disclosure also contemplates other antibodies and antibody fragments, such as:
  • T cell receptors have two V-domains that combine into a structure similar to the Fv module of an antibody.
  • Novotny et al., Proc Natl Acad Sci USA 88: 8646-8650, 1991 describes how the two V-domains of the T-cell receptor (termed alpha and beta) can be fused and expressed as a single chain polypeptide and, further, how to alter surface residues to reduce the hydrophobicity directly analogous to an antibody scFv.
  • Other publications describing production of single-chain T-cell receptors or multimeric T cell receptors comprising two V-alpha and V-beta domains include WO1999/045110 or WO2011/107595.
  • non-antibody proteins comprising antigen binding domains include proteins with V-like domains, which are generally monomeric. Examples of proteins comprising such V-like domains include CTLA-4, CD28 and ICOS. Further disclosure of proteins comprising such V-like domains is included in WO1999/045110.
  • a compound of the disclosure is an adnectin.
  • Adnectins are based on the tenth fibronectin type III ( 10 Fn3) domain of human fibronectin in which the loop regions are altered to confer antigen binding.
  • 10 Fn3 domain the tenth fibronectin type III
  • three loops at one end of the ⁇ -sandwich of the 10 Fn3 domain can be engineered to enable an Adnectin to specifically recognize an antigen.
  • a compound of the disclosure is an anticalin.
  • Anticalins are derived from lipocalins, which are a family of extracellular proteins which transport small hydrophobic molecules such as steroids, bilins, retinoids and lipids. Lipocalins have a rigid p-sheet secondary structure with a plurality of loops at the open end of the conical structure which can be engineered to bind to an antigen. Such engineered lipocalins are known as anticalins.
  • anticalins see U.S. Pat. No. 7,250,297B1 or US20070224633.
  • a compound of the disclosure is an affibody.
  • An affibody is a scaffold derived from the Z domain (antigen binding domain) of Protein A of Staphylococcus aureus which can be engineered to bind to antigen.
  • the Z domain consists of a three-helical bundle of approximately 58 amino acids. Libraries have been generated by randomization of surface residues. For further details see EP1641818.
  • a compound of the disclosure is an Avimer.
  • Avimers are multidomain proteins derived from the A-domain scaffold family. The native domains of approximately 35 amino acids adopt a defined disulfide bonded structure. Diversity is generated by shuffling of the natural variation exhibited by the family of A-domains. For further details see WO2002088171.
  • a compound of the disclosure is a Designed Ankyrin Repeat Protein (DARPin).
  • DARPins are derived from Ankyrin which is a family of proteins that mediate attachment of integral membrane proteins to the cytoskeleton.
  • a single ankyrin repeat is a 33 residue motif consisting of two a-helices and a ⁇ -turn. They can be engineered to bind different target antigens by randomizing residues in the first ⁇ -helix and a ⁇ -turn of each repeat. Their binding interface can be increased by increasing the number of modules (a method of affinity maturation). For further details see US20040132028.
  • the present disclosure also contemplates a soluble form of the G-CSFR which competes with the naturally occurring membrane-associated G-CSFR for G-CSF interaction.
  • soluble forms of the receptor see for example U.S. Pat. No. 5,589,456 and Honjo et al, Acta Crystallograph Sect F Struct Biol Cryst Commun. 61(Pt 8):788-790, 2005.
  • the present disclosure also contemplates a de-immunized antibody or protein.
  • De-immunized antibodies and proteins have one or more epitopes, e.g., B cell epitopes or T cell epitopes removed (i.e., mutated) to thereby reduce the likelihood that a mammal will raise an immune response against the antibody or protein.
  • epitopes e.g., B cell epitopes or T cell epitopes removed (i.e., mutated) to thereby reduce the likelihood that a mammal will raise an immune response against the antibody or protein.
  • Methods for producing de-immunized antibodies and proteins are known in the art and described, for example, in WO2000/34317, WO2004/108158 and WO2004/064724.
  • the present disclosure also contemplates mutant forms of a protein of the disclosure.
  • data presented herein indicate sites within a CDR of a protein of the disclosure that can be changed in addition to exemplary changes that can be made.
  • changes can additionally or alternatively be made within a framework region of a variable region containing protein without inhibiting or significantly reducing its function in the context of the present disclosure.
  • such a mutant protein comprises one or more conservative amino acid substitutions compared to a sequence set forth herein.
  • the protein comprises 30 or fewer or 20 or fewer or 10 or fewer, e.g., 9 or 8 or 7 or 6 or 5 or 4 or 3 or 2 conservative amino acid substitutions.
  • a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain and/or hydropathicity and/or hydrophilicity.
  • a mutant protein has only, or not more than, one or two or three or four or five or six conservative amino acid changes when compared to a naturally occurring protein. Details of conservative amino acid changes are provided below. As the skilled person would be aware, e.g., from the disclosure herein, such minor changes can reasonably be predicted not to alter the activity of the protein.
  • Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), ⁇ -branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
  • basic side chains e.g., lysine, arginine, histidine
  • acidic side chains e.g., aspartic
  • the present disclosure also contemplates non-conservative amino acid changes (e.g., substitutions) in a protein of the present disclosure, e.g., in a CDR, such as CDR3.
  • a CDR such as CDR3
  • the present inventors have identified several non-conservative amino acid substitutions that can be made while retaining an activity of a protein of the disclosure.
  • the protein comprises fewer than 6 or 5 or 4 or 3 or 2 or 1 non-conservative amino acid substitutions, e.g., in a CDR3, such as in a CDR3.
  • the present disclosure also contemplates one or more insertions or deletions compared to a sequence set forth herein.
  • the protein comprises 10 or fewer, e.g., 9 or 8 or 7 or 6 or 5 or 4 or 3 or 2 insertions and/or deletions.
  • the present disclosure encompasses proteins and/or antibodies described herein comprising a constant region of an antibody. This includes antigen binding fragments of an antibody fused to a Fc.
  • the constant region or portion thereof of the protein is derived from a human antibody.
  • the constant region or portion thereof may be derived from any antibody class, including IgM, IgG, IgD, IgA and IgE, and any antibody isotype, including IgG1, IgG2, IgG3 and IgG4.
  • the constant region is human isotype IgG4 or a stabilized IgG4 constant region.
  • the Fc region of the constant region has a reduced ability to induce effector function, e.g., compared to a native or wild-type human IgG1 or IgG3 Fc region.
  • the effector function is antibody-dependent cell-mediated cytotoxicity (ADCC) and/or antibody-dependent cell-mediated phagocytosis (ADCP) and/or complement-dependent cytotoxicity (CDC).
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • ADCP antibody-dependent cell-mediated phagocytosis
  • CDC complement-dependent cytotoxicity
  • the Fc region is an IgG4 Fc region (i.e., from an IgG4 constant region), e.g., a human IgG4 Fc region. Sequences of suitable IgG4 Fc regions will be apparent to the skilled person and/or available in publically available databases (e.g., available from National Center for Biotechnology Information).
  • the constant region is a stabilized IgG4 constant region.
  • stabilized IgG4 constant region will be understood to mean an IgG4 constant region that has been modified to reduce Fab arm exchange or the propensity to undergo Fab arm exchange or formation of a half-antibody or a propensity to form a half antibody.
  • Fab arm exchange refers to a type of protein modification for human IgG4, in which an IgG4 heavy chain and attached light chain (half-molecule) is swapped for a heavy-light chain pair from another IgG4 molecule.
  • IgG4 molecules may acquire two distinct Fab arms recognizing two distinct antigens (resulting in bispecific molecules).
  • Fab arm exchange occurs naturally in vivo and can be induced in vitro by purified blood cells or reducing agents such as reduced glutathione.
  • a “half antibody” forms when an IgG4 antibody dissociates to form two molecules each containing a single heavy chain and a single light chain.
  • a stabilized IgG4 constant region comprises a proline at position 241 of the hinge region according to the system of Kabat (Kabat et al., Sequences of Proteins of Immunological Interest Washington D.C. United States Department of Health and Human Services, 1987 and/or 1991). This position corresponds to position 228 of the hinge region according to the EU numbering system (Kabat et al., Sequences of Proteins of Immunological Interest Washington D.C. United States Department of Health and Human Services, 2001 and Edelman et al., Proc. Natl. Acad. USA, 63, 78-85, 1969). In human IgG4, this residue is generally a serine.
  • the IgG4 hinge region comprises a sequence CPPC.
  • the “hinge region” is a proline-rich portion of an antibody heavy chain constant region that links the Fc and Fab regions that confers mobility on the two Fab arms of an antibody.
  • the hinge region includes cysteine residues which are involved in inter-heavy chain disulfide bonds. It is generally defined as stretching from Glu226 to Pro243 of human IgG1 according to the numbering system of Kabat.
  • Hinge regions of other IgG isotypes may be aligned with the IgG1 sequence by placing the first and last cysteine residues forming inter-heavy chain disulphide (S—S) bonds in the same positions (see for example WO2010/080538).
  • S—S inter-heavy chain disulphide
  • stabilized IgG4 antibodies are antibodies in which arginine at position 409 in a heavy chain constant region of human IgG4 (according to the EU numbering system) is substituted with lysine, threonine, methionine, or leucine (e.g., as described in WO2006/033386).
  • the Fc region of the constant region may additionally or alternatively comprise a residue selected from the group consisting of: alanine, valine, glycine, isoleucine and leucine at the position corresponding to 405 (according to the EU numbering system).
  • the hinge region comprises a proline at position 241 (i.e., a CPPC sequence) (as described above).
  • the Fc region is a region modified to have reduced effector function, i.e., a “non-immunostimulatory Fc region”.
  • the Fc region is an IgG1 Fc region comprising a substitution at one or more positions selected from the group consisting of 268, 309, 330 and 331.
  • the Fc region is an IgG1 Fc region comprising one or more of the following changes E233P, L234V, L235A and deletion of G236 and/or one or more of the following changes A327G, A330S and P331S (Armour et al., Eur J Immunol.
  • the Fc region is a chimeric Fc region, e.g., comprising at least one C H 2 domain from an IgG4 antibody and at least one C H 3 domain from an IgG1 antibody, wherein the Fc region comprises a substitution at one or more amino acid positions selected from the group consisting of 240, 262, 264, 266, 297, 299, 307, 309, 323, 399, 409 and 427 (EU numbering) (e.g., as described in WO2010/085682).
  • Exemplary substitutions include 240F, 262L, 264T, 266F, 297Q, 299A, 299K, 307P, 309K, 309M, 309P, 323F, 399S, and 427F.
  • the present disclosure also contemplates additional modifications to an antibody or protein of the disclosure.
  • the antibody comprises one or more amino acid substitutions that increase the half-life of the protein.
  • the antibody comprises a Fc region comprising one or more amino acid substitutions that increase the affinity of the Fc region for the neonatal Fc region (FcRn).
  • the Fc region has increased affinity for FcRn at lower pH, e.g., about pH 6.0, to facilitate Fc/FcRn binding in an endosome.
  • the Fc region has increased affinity for FcRn at about pH 6 compared to its affinity at about pH 7.4, which facilitates the re-release of Fc into blood following cellular recycling.
  • Exemplary amino acid substitutions include T250Q and/or M428L or T252A, T254S and T266F or M252Y, S254T and T256E or H433K and N434F according to the EU numbering system. Additional or alternative amino acid substitutions are described, for example, in US20070135620 or U.S. Pat. No. 7,083,784.
  • the protein of the disclosure additionally comprises albumin, a functional fragment or variant thereof.
  • the albumin, functional fragment or variant thereof is serum albumin, such as human serum albumin.
  • the albumin, functional fragment or variant thereof comprises one or more amino acid substitutions, deletions or insertions, e.g., no more than 5 or 4 or 3 or 2 or 1 substitutions.
  • Amino acid substitutions suitable for use in the present disclosure will be apparent to the skilled person and include naturally-occurring substitutions and engineered substitutions such as those described, for example, in WO2011051489, WO2014072481, WO2011103076, WO2012112188, WO2013075066, WO2015063611 and WO2014179657.
  • a protein described herein according to any example is produced by culturing a hybridoma under conditions sufficient to produce the protein, e.g., as described herein and/or as is known in the art.
  • a protein described herein according to any example is recombinant.
  • nucleic acid encoding same can be cloned into expression constructs or vectors, which are then transfected into host cells, such as E. coli cells, yeast cells, insect cells, or mammalian cells, such as simian COS cells, Chinese Hamster Ovary (CHO) cells, human embryonic kidney (HEK) cells, or myeloma cells that do not otherwise produce the protein.
  • host cells such as E. coli cells, yeast cells, insect cells, or mammalian cells, such as simian COS cells, Chinese Hamster Ovary (CHO) cells, human embryonic kidney (HEK) cells, or myeloma cells that do not otherwise produce the protein.
  • exemplary cells used for expressing a protein are CHO cells, myeloma cells or HEK cells.
  • Molecular cloning techniques to achieve these ends are known in the art and described, for example in Ausubel et al., (editors), Current Protocols in Molecular Biology, Greene Pub.
  • nucleic acid is inserted operably linked to a promoter in an expression construct or expression vector for further cloning (amplification of the DNA) or for expression in a cell-free system or in cells.
  • promoter is to be taken in its broadest context and includes the transcriptional regulatory sequences of a genomic gene, including the TATA box or initiator element, which is required for accurate transcription initiation, with or without additional regulatory elements (e.g., upstream activating sequences, transcription factor binding sites, enhancers and silencers) that alter expression of a nucleic acid, e.g., in response to a developmental and/or external stimulus, or in a tissue specific manner.
  • promoter is also used to describe a recombinant, synthetic or fusion nucleic acid, or derivative which confers, activates or enhances the expression of a nucleic acid to which it is operably linked.
  • Exemplary promoters can contain additional copies of one or more specific regulatory elements to further enhance expression and/or alter the spatial expression and/or temporal expression of said nucleic acid.
  • operably linked to means positioning a promoter relative to a nucleic acid such that expression of the nucleic acid is controlled by the promoter.
  • the vector components generally include, but are not limited to, one or more of the following: a signal sequence, a sequence encoding a protein (e.g., derived from the information provided herein), an enhancer element, a promoter, and a transcription termination sequence.
  • a signal sequence e.g., a sequence encoding a protein (e.g., derived from the information provided herein)
  • an enhancer element e.g., derived from the information provided herein
  • a promoter e.g., derived from the information provided herein
  • a transcription termination sequence e.g., a transcription termination sequence.
  • Exemplary signal sequences include prokaryotic secretion signals (e.g., pelB, alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II), yeast secretion signals (e.g., invertase leader, ⁇ factor leader, or acid phosphatase leader) or mammalian secretion signals (e.g., herpes simplex gD signal).
  • prokaryotic secretion signals e.g., pelB, alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II
  • yeast secretion signals e.g., invertase leader, ⁇ factor leader, or acid phosphatase leader
  • mammalian secretion signals e.g., herpes simplex gD signal.
  • Exemplary promoters active in mammalian cells include cytomegalovirus immediate early promoter (CMV-IE), human elongation factor 1- ⁇ promoter (EF1), small nuclear RNA promoters (U1a and U1b), ⁇ -myosin heavy chain promoter, Simian virus 40 promoter (SV40), Rous sarcoma virus promoter (RSV), Adenovirus major late promoter, ⁇ -actin promoter; hybrid regulatory element comprising a CMV enhancer/ ⁇ -actin promoter or an immunoglobulin promoter or active fragment thereof.
  • CMV-IE cytomegalovirus immediate early promoter
  • EF1 human elongation factor 1- ⁇ promoter
  • U1a and U1b small nuclear RNA promoters
  • ⁇ -myosin heavy chain promoter ⁇ -myosin heavy chain promoter
  • Simian virus 40 promoter SV40
  • Rous sarcoma virus promoter RSV
  • Adenovirus major late promoter ⁇ -
  • Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture; baby hamster kidney cells (BHK, ATCC CCL 10); or Chinese hamster ovary cells (CHO).
  • COS-7 monkey kidney CV1 line transformed by SV40
  • human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture
  • baby hamster kidney cells BHK, ATCC CCL 10
  • Chinese hamster ovary cells CHO
  • Typical promoters suitable for expression in yeast cells such as for example a yeast cell selected from the group comprising Pichia pastoris, Saccharomyces cerevisiae and S. pombe , include, but are not limited to, the ADH1 promoter, the GAL1 promoter, the GAL4 promoter, the CUP1 promoter, the PHO5 promoter, the nmt promoter, the RPR1 promoter, or the TEF promoter.
  • Means for introducing the isolated nucleic acid or expression construct comprising same into a cell for expression are known to those skilled in the art. The technique used for a given cell depends on the known successful techniques. Means for introducing recombinant DNA into cells include microinjection, transfection mediated by DEAE-dextran, transfection mediated by liposomes such as by using lipofectamine (Gibco, MD, USA) and/or cellfectin (Gibco, MD, USA), PEG-mediated DNA uptake, electroporation and microparticle bombardment such as by using DNA-coated tungsten or gold particles (Agracetus Inc., WI, USA) amongst others.
  • the host cells used to produce the protein may be cultured in a variety of media, depending on the cell type used.
  • Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing mammalian cells.
  • Media for culturing other cell types discussed herein are known in the art.
  • supernatants from such expression systems can be first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit.
  • a protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis and antibiotics may be included to prevent the growth of adventitious contaminants.
  • supernatants can be filtered and/or separated from cells expressing the protein, e.g., using continuous centrifugation.
  • the protein prepared from the cells can be purified using, for example, ion exchange, hydroxyapatite chromatography, hydrophobic interaction chromatography, gel electrophoresis, dialysis, affinity chromatography (e.g., protein A affinity chromatography or protein G chromatography), or any combination of the foregoing.
  • affinity chromatography e.g., protein A affinity chromatography or protein G chromatography
  • a protein can be modified to include a tag to facilitate purification or detection, e.g., a poly-histidine tag, e.g., a hexa-histidine tag, or a influenza virus hemagglutinin (HA) tag, or a Simian Virus 5 (V5) tag, or a FLAG tag, or a glutathione S-transferase (GST) tag.
  • a poly-histidine tag e.g., a hexa-histidine tag, or a influenza virus hemagglutinin (HA) tag, or a Simian Virus 5 (V5) tag, or a FLAG tag, or a glutathione S-transferase (GST) tag.
  • HA hemagglutinin
  • V5 Simian Virus 5
  • FLAG tag e.g., a FLAG tag
  • GST glutathione S-transferase
  • a protein comprising a hexa-his tag is purified by contacting a sample comprising the protein with nickel-nitrilotriacetic acid (Ni-NTA) that specifically binds a hexa-his tag immobilized on a solid or semi-solid support, washing the sample to remove unbound protein, and subsequently eluting the bound protein.
  • Ni-NTA nickel-nitrilotriacetic acid
  • a ligand or antibody that binds to a tag is used in an affinity purification method.
  • therapeutic and/or prophylactic methods as described herein according to any example of the disclosure involve reducing expression of G-CSF and/or G-CSFR.
  • a method involves administering a compound that reduces transcription and/or translation of a nucleic acid encoding G-CSF or G-CSFR.
  • the compound that inhibits G-CSF signaling is a nucleic acid, e.g., an antisense polynucleotide, a ribozyme, a PNA, an interfering RNA, a siRNA, a microRNA.
  • the compound that inhibits G-CSF signaling is a nucleic acid encoding a protein compound that inhibits G-CSF signaling (e.g., an antibody or antigen binding fragment thereof).
  • antisense nucleic acid shall be taken to mean a DNA or RNA or derivative thereof (e.g., LNA or PNA), or combination thereof that is complementary to at least a portion of a specific mRNA molecule encoding a polypeptide as described herein in any example of the disclosure and capable of interfering with a post-transcriptional event such as mRNA translation.
  • Antisense nucleic acid of the disclosure will hybridize to a target nucleic acid under physiological conditions.
  • Antisense nucleic acids include sequences that correspond to structural genes or coding regions or to sequences that effect control over gene expression or splicing.
  • the antisense nucleic acid may correspond to the targeted coding region of a nucleic acid encoding G-CSF or G-CSFR, or the 5′-untranslated region (UTR) or the 3′-UTR or combination of these. It may be complementary in part to intron sequences, which may be spliced out during or after transcription, for example only to exon sequences of the target gene.
  • the length of the antisense sequence should be at least 19 contiguous nucleotides, for example, at least 50 nucleotides, such as at least 100, 200, 500 or 1000 nucleotides of a nucleic acid encoding G-CSF or G-CSFR.
  • the full-length sequence complementary to the entire gene transcript may be used.
  • the length can be 100-2000 nucleotides.
  • the degree of identity of the antisense sequence to the targeted transcript should be at least 90%, for example, 95-100%.
  • antisense nucleic acids against G-CSF or G-CSFR are described, for example, in WO2011032204.
  • catalytic nucleic acid refers to a DNA molecule or DNA-containing molecule (also known in the art as a “deoxyribozyme” or “DNAzyme”) or a RNA or RNA-containing molecule (also known as a “ribozyme” or “RNAzyme”) which specifically recognizes a distinct substrate and catalyzes the chemical modification of this substrate.
  • the nucleic acid bases in the catalytic nucleic acid can be bases A, C, G, T (and U for RNA).
  • the catalytic nucleic acid contains an antisense sequence for specific recognition of a target nucleic acid, and a nucleic acid cleaving enzymatic activity (also referred to herein as the “catalytic domain”).
  • a nucleic acid cleaving enzymatic activity also referred to herein as the “catalytic domain”.
  • the types of ribozymes that are useful in this disclosure are a hammerhead ribozyme and a hairpin ribozyme.
  • RNA interference is useful for specifically inhibiting the production of a particular protein.
  • this technology relies on the presence of dsRNA molecules that contain a sequence that is essentially identical to the mRNA of the gene of interest or part thereof, in this case an mRNA encoding G-CSF or G-CSFR.
  • the dsRNA can be produced from a single promoter in a recombinant vector host cell, where the sense and anti-sense sequences are flanked by an unrelated sequence which enables the sense and anti-sense sequences to hybridize to form the dsRNA molecule with the unrelated sequence forming a loop structure.
  • dsRNA molecules for RNAi include, but are not limited to short hairpin RNA (shRNA) and bi-functional shRNA.
  • the length of the sense and antisense sequences that hybridize should each be at least 19 contiguous nucleotides, such as at least 30 or 50 nucleotides, for example at least 100, 200, 500 or 1000 nucleotides.
  • the full-length sequence corresponding to the entire gene transcript may be used.
  • the lengths can be 100-2000 nucleotides.
  • the degree of identity of the sense and antisense sequences to the targeted transcript should be at least 85%, for example, at least 90% such as, 95-100%.
  • siRNA molecules comprise a nucleotide sequence that is identical to about 19-21 contiguous nucleotides of the target mRNA.
  • the siRNA sequence commences with the dinucleotide AA, comprises a GC-content of about 30-70% (for example, 30-60%, such as 40-60% for example about 45%-55%), and does not have a high percentage identity to any nucleotide sequence other than the target in the genome of the mammal in which it is to be introduced, for example as determined by standard BLAST search.
  • a compound is a nucleic acid aptamer (adaptable oligomer).
  • Aptamers are single stranded oligonucleotides or oligonucleotide analogs that are capable of forming a secondary and/or tertiary structure that provides the ability to bind to a particular target molecule, such as a protein or a small molecule, e.g., G-CSF or G-CSFR.
  • aptamers are the oligonucleotide analogy to antibodies.
  • aptamers comprise about 15 to about 100 nucleotides, such as about 15 to about 40 nucleotides, for example about 20 to about 40 nucleotides, since oligonucleotides of a length that falls within these ranges can be prepared by conventional techniques.
  • An aptamer can be isolated from or identified from a library of aptamers.
  • An aptamer library is produced, for example, by cloning random oligonucleotides into a vector (or an expression vector in the case of an RNA aptamer), wherein the random sequence is flanked by known sequences that provide the site of binding for PCR primers.
  • An aptamer that provides the desired biological activity e.g., binds specifically to G-CSF or G-CSFR
  • An aptamer with increased activity is selected, for example, using SELEX (Sytematic Evolution of Ligands by EXponential enrichment).
  • Suitable methods for producing and/or screening an aptamer library are described, for example, in Elloington and Szostak, Nature 346:818-22, 1990; U.S. Pat. No. 5,270,163; and/or U.S. Pat. No. 5,475,096.
  • some compounds of the present disclosure bind to the ligand binding domain of hG-CSFR and to specific mutant forms of the ligand binding domain of hG-CSFR (e.g., SEQ ID NO: 1 without or with certain point mutations) and/or bind to both human and cynomolgus monkey G-CSFR.
  • Methods for assessing binding to a protein are known in the art, e.g., as described in Scopes (In: Protein purification: principles and practice, Third Edition, Springer Verlag, 1994). Such a method generally involves labeling the protein and contacting it with immobilized compound.
  • the protein can be immobilized and the compound that inhibits G-CSF signaling labeled.
  • Panning-type assays can also be used.
  • surface plasmon resonance assays can be used.
  • the assays described above can also be used to detect the level of binding of a compound to hG-CSFR or a ligand binding domain thereof (e.g., SEQ ID NO: 1) or mutant form thereof.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the lysine at position 167 of SEQ ID NO: 1 and/or in which an alanine is substituted for the histidine at position 168 of SEQ ID NO: 1 at substantially the same level (e.g., within 10% or 5% or 1%) as it binds to SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the arginine at position 287 of SEQ ID NO: 1 at a level at least about 100 fold or 150 fold or 160 fold or 200 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the arginine at position 287 of SEQ ID NO: 1 at a level at least about 160 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the histidine at position 237 of SEQ ID NO: 1 at a level at least about 20 fold or 40 fold or 50 fold or 60 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the histidine at position 237 of SEQ ID NO: 1 at a level at least about 50 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the methionine at position 198 of SEQ ID NO: 1 at a level at least about 20 fold or 40 fold or 60 fold or 70 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the methionine at position 198 of SEQ ID NO: 1 at a level at least about 40 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the tyrosine at position 172 of SEQ ID NO: 1 at a level at least about 20 fold or 30 fold or 40 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the tyrosine at position 172 of SEQ ID NO: 1 at a level at least about 40 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the leucine at position 171 of SEQ ID NO: 1 at a level at least about 100 fold or 120 fold or 130 fold or 140 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the leucine at position 171 of SEQ ID NO: 1 at a level at least about 140 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the leucine at a position 111 of SEQ ID NO: 1 at a level at least about 20 fold or 40 fold or 60 fold or 70 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the leucine at a position 111 of SEQ ID NO: 1 at a level at least about 60 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the histidine at position 168 of SEQ ID NO: 1 at a level no more than 5 fold or 4 fold or 3 fold or 2 fold or 1 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • a protein of the present disclosure binds to a polypeptide of SEQ ID NO: 1 in which an alanine is substituted for the lysine at position 167 of SEQ ID NO: 1 at a level no more than 5 fold or 4 fold or 3 fold or 2 fold or 1 fold lower than it binds to a polypeptide of SEQ ID NO: 1.
  • the level of binding is conveniently determined using a biosensor.
  • a protein described herein has all of the binding characteristics set forth in the preceding seven paragraphs.
  • the epitope bound by a protein described herein is mapped.
  • Epitope mapping methods will be apparent to the skilled artisan. For example, a series of overlapping peptides spanning the hG-CSFR sequence or a region thereof comprising an epitope of interest, e.g., peptides comprising 10-15 amino acids are produced. The protein is then contacted to each peptide and the peptide(s) to which it binds determined. This permits determination of peptide(s) comprising the epitope to which the protein binds. If multiple non-contiguous peptides are bound by the protein, the protein may bind a conformational epitope.
  • amino acid residues within hG-CSFR are mutated, e.g., by alanine scanning mutagenesis, and mutations that reduce or prevent protein binding are determined. Any mutation that reduces or prevents binding of the protein is likely to be within the epitope bound by the protein.
  • a further method is exemplified herein, and involves binding hG-CSFR or a region thereof to an immobilized protein of the present disclosure and digesting the resulting complex with proteases. Peptide that remains bound to the immobilized protein are then isolated and analyzed, e.g., using mass spectrometry, to determine their sequence.
  • a further method involves converting hydrogens in hG-CSFR or a region thereof to deutrons and binding the resulting protein to an immobilized protein of the present disclosure.
  • the deutrons are then converted back to hydrogen, the hG-CSFR or region thereof isolated, digested with enzymes and analyzed, e.g., using mass spectrometry to identify those regions comprising deutrons, which would have been protected from conversion to hydrogen by the binding of a protein described herein.
  • the dissociation constant (Kd) of a protein for hG-CSFR or an epitope thereof is determined.
  • the “Kd” or “Kd value” for a hG-CSFR binding protein is in one example measured by a radiolabeled or fluorescently-labeled hG-CSFR binding assay. This assay equilibrates the protein with a minimal concentration of labeled G-CSFR in the presence of a titration series of unlabeled hG-CSFR. Following washing to remove unbound hG-CSFR, the amount of label is determined, which is indicative of the Kd of the protein.
  • the Kd or Kd value is measured by using surface plasmon resonance assays, e.g., using BIAcore surface plasmon resonance (BIAcore, Inc., Piscataway, N.J.) with immobilized hG-CSFR or a region thereof.
  • surface plasmon resonance assays e.g., using BIAcore surface plasmon resonance (BIAcore, Inc., Piscataway, N.J.) with immobilized hG-CSFR or a region thereof.
  • proteins having a similar Kd or a higher Kd than C1.2 or C1.2G are selected, because they are likely to compete for binding to hG-CSFR.
  • C1.2 or C1.2G is conjugated to a detectable label, e.g., a fluorescent label or a radioactive label.
  • the labeled antibody and the test protein are then mixed and contacted with hG-CSFR or a region thereof (e.g., a polypeptide comprising SEQ ID NO: 1) or a cell expressing same.
  • the level of labeled C1.2 or C1.2G is then determined and compared to the level determined when the labeled antibody is contacted with the hG-CSFR, region or cells in the absence of the protein. If the level of labeled C1.2 or C1.2G is reduced in the presence of the test protein compared to the absence of the protein, the protein is considered to competitively inhibit binding of C1.2 or C1.2G to hG-CSFR.
  • test protein is conjugated to different label to C1.2 or C1.2G.
  • This alternate labeling permits detection of the level of binding of the test protein to hG-CSFR or the region thereof or the cell.
  • the protein is permitted to bind to hG-CSFR or a region thereof (e.g., a polypeptide comprising SEQ ID NO: 1) or a cell expressing same prior to contacting the hG-CSFR, region or cell with C1.2 or C1.2G.
  • a reduction in the amount of bound C1.2 or C1.2G in the presence of the protein compared to in the absence of the protein indicates that the protein competitively inhibits C1.2 or C1.2G binding to hG-CSFR.
  • a reciprocal assay can also be performed using labeled protein and first allowing C1.2 or C1.2G to bind to G-CSFR.
  • a reduced amount of labeled protein bound to hG-CSFR in the presence of C1.2 or C1.2G compared to in the absence of C1.2 or C1.2G indicates that the protein competitively inhibits binding of C1.2 or C1.2G to hG-CSFR.
  • any of the foregoing assays can be performed with a mutant form of hG-CSFR and/or SEQ ID NO: 1 and/or a ligand binding region of hG-CSFR to which C1.2 or C1.2G binds, e.g., as described herein.
  • a compound is capable of neutralizing hG-CSFR signaling.
  • the compound that inhibits G-CSF signaling reduces or prevents G-CSF binding to the hG-CSFR.
  • assays can be performed as a competitive binding assay as described herein using labeled G-CSF and/or labeled protein.
  • the compound that inhibits G-CSF signaling reduces formation of CFU-G when CD34 + bone marrow cells are cultured in the presence of G-CSF.
  • CD34 + bone marrow cells are cultured in a semi-solid cell culture medium in the presence of G-CSF (e.g., about 10 ng/ml cell culture medium) and, optionally stem cell factor (e.g., about 10 ng/ml cell culture medium) in the presence or absence of a test compound.
  • G-CSF e.g., about 10 ng/ml cell culture medium
  • stem cell factor e.g., about 10 ng/ml cell culture medium
  • an IC 50 is determined, i.e., a concentration at which 50% of the maximum inhibition of CFU-G formation occurs.
  • the IC 50 is 0.2 nM or less, such as 0.1 nM or less, for example, 0.09 nM or less, or 0.08 nM or less, or 0.07 nM or less, or 0.06 nM or less or 0.05 nM or less.
  • the IC 50 is 0.04 nM or less.
  • the IC 50 is 0.02 nM or less.
  • the compound that inhibits G-CSF signaling reduces proliferation of cells (e.g., BaF3 cells) expressing hG-CSFR which are cultured in the presence of G-CSF.
  • Cells are cultured in the presence of G-CSF (e.g., 0.5 ng/ml) and the presence or absence of a test compound.
  • G-CSF e.g., 0.5 ng/ml
  • Methods for assessing cell proliferation include, for example, MTT reduction and thymidine incorporation.
  • a compound that reduces the level of proliferation compared to the level observed in the absence of the compound is considered to neutralize G-CSF signaling.
  • an IC 50 is determined, i.e., a concentration at which 50% of the maximum inhibition of cell proliferation occurs.
  • the IC 50 is 6 nM or less, such as 5.9 nM or less. In another example, the IC 50 is 2 nM or less or 1 nM or less or 0.7 nM or cell or 0.6 nM or less or 0.5 nM or less.
  • the foregoing IC 50 s relate to any cell proliferation assay described herein.
  • the compound that inhibits G-CSF signaling reduces mobilization of hematopoietic stem cells and/or endothelial progenitor cells in vivo following G-CSF administration and/or reduces the number of neutrophils in vivo, e.g., following G-CSF administration (however this is not essential).
  • the compound that inhibits G-CSF signaling is administered, optionally before, at the time of or after administration of G-CSF or a modified form thereof (e.g., PEGylated G-CSF or filgrastim).
  • the number of hematopoietic stem cells e.g., expressing CD34 and/or Thy1 and/or endothelial progenitor cells (e.g., expressing CD34 and VEGFR2) and/or neutrophils (identified morphologically and/or expressing e.g., CD10, CD14, CD31 and/or CD88) is assessed.
  • a compound that reduces the level of the cell(s) compared to the level observed in the absence of the compound is considered to neutralize G-CSF signaling.
  • the compound that inhibits G-CSF signaling reduces the number of neutrophils without inducing neutropenia.
  • ADCC activity As discussed herein, some proteins of the present disclosure have reduced effector function. Methods for assessing ADCC activity are known in the art.
  • the level of ADCC activity is assessed using a 51 Cr release assay, an europium release assay or a 35 S release assay.
  • cells expressing G-CSFR are cultured with one or more of the recited compounds that inhibit G-CSF signaling for a time and under conditions sufficient for the compound to be taken up by the cell.
  • cells expressing hG-CSFR can be cultured with 35 S-labeled methionine and/or cysteine for a time sufficient for the labeled amino acids to be incorporated into newly synthesized proteins.
  • PBMC peripheral blood mononuclear cells
  • NK cells e.g., PBMC
  • the amount of 51 Cr, europium and/or 35 S in cell culture medium is then detected, and little or no change in the presence of the protein compared to in the absence of protein (or a reduced level of the compound compared to the level observed in the presence of an anti-hG-CSFR antibody comprising a human IgG1 Fc) indicates that the protein has reduced effector function.
  • Exemplary publications disclosing assays for assessing the level of ADCC induced by a protein include Hellstrom, et al. Proc. Natl Acad. Sci. USA 83:7059-7063, 1986 and Bruggemann, et al., J. Exp. Med. 166:1351-1361, 1987.
  • ACTITM nonradioactive cytotoxicity assay for flow cytometry CellTechnology, Inc. CA, USA
  • CytoTox 96® non-radioactive cytotoxicity assay Promega, WI, USA
  • C1q binding assays may also be carried out to confirm that the protein is able to bind C1q and may induce CDC.
  • a CDC assay may be performed (see, for example, Gazzano-Santoro et al, J. Immunol. Methods 202: 163, 1996.
  • Some proteins encompassed by the present disclosure have an improved half-life, e.g., are modified to extend their half-life compared to proteins that are unmodified. Methods for determining a protein with an improved half-life will be apparent to the skilled person. For example, the ability of a protein to bind to a neonatal Fc receptor (FcRn) is assessed. In this regard, increased binding affinity for FcRn increased the serum half-life of the molecule (see for example, Kim et al., Eur J Immunol., 24:2429, 1994).
  • FcRn neonatal Fc receptor
  • the half-life of a protein of the disclosure can also be measured by pharmacokinetic studies, e.g., according to the method described by Kim et al, Eur J of Immunol 24:542, 1994. According to this method radiolabeled protein is injected intravenously into mice and its plasma concentration is periodically measured as a function of time, for example at 3 minutes to 72 hours after the injection.
  • the clearance curve thus obtained should be biphasic, that is, an alpha phase and beta phase.
  • the clearance rate in beta-phase is calculated and compared with that of the wild type or unmodified protein.
  • the efficacy of a compound to treat ischemia-reperfusion injury can be assessed using an in vivo assay. For example, by using a mouse model as described in Bohl et al., Am J Physiol Heart Circ Physiol (2009), Hartsock et al., J Vis Exp (2016), Greenberg et al., Methods Enzymol (2008), or Zhang et al., The FASEB Journal (2016).
  • a compound as described herein can be administered orally, parenterally, by inhalation spray, adsorption, absorption, topically, rectally, nasally, bucally, vaginally, intraventricularly, via an implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically-acceptable carriers, or by any other convenient dosage form.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal, and intracranial injection or infusion techniques.
  • Methods for preparing a compound into a suitable form for administration are known in the art and include, for example, methods as described in Remington's Pharmaceutical Sciences (18th ed., Mack Publishing Co., Easton, Pa., 1990) and U.S. Pharmacopeia: National Formulary (Mack Publishing Company, Easton, Pa., 1984).
  • compositions of this disclosure are particularly useful for parenteral administration, such as intravenous administration or subcutaneous administration or administration into a body cavity or lumen of an organ or joint.
  • the compositions for administration will commonly comprise a solution of the compound that inhibits G-CSF signaling dissolved in a pharmaceutically acceptable carrier, for example an aqueous carrier.
  • a pharmaceutically acceptable carrier for example an aqueous carrier.
  • aqueous carriers can be used, e.g., buffered saline and the like.
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
  • concentration of compound of the present disclosure in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.
  • exemplary carriers include water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin.
  • Nonaqueous vehicles such as mixed oils and ethyl oleate may also be used.
  • Liposomes may also be used as carriers.
  • the vehicles may contain minor amounts of additives that enhance isotonicity and chemical stability, e.g., buffers and preservatives.
  • compounds of the present disclosure will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically/prophylactically effective.
  • Formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but other pharmaceutically acceptable forms are also contemplated, e.g., tablets, pills, capsules or other solids for oral administration, suppositories, pessaries, nasal solutions or sprays, aerosols, inhalants, liposomal forms and the like.
  • Pharmaceutical “slow release” capsules or compositions may also be used. Slow release formulations are generally designed to give a constant drug level over an extended period and may be used to deliver compounds of the present disclosure.
  • WO2002/080967 describes compositions and methods for administering aerosolized compositions comprising antibodies for the treatment of, e.g., asthma, which are also suitable for administration of a protein of the present disclosure.
  • a compound of the present disclosure is administered in combination with another compound useful for treating a disease or condition described herein, either as combined or additional treatment steps or as additional components of a therapeutic formulation.
  • the other compound is an anti-inflammatory compound.
  • the other compound is an immunosuppressant.
  • the other compound is a corticosteroid, such as prednisone and/or prednisolone.
  • the other compound is methotrexate.
  • the other compound is cyclophosphamide.
  • the other compound is mycophenolate mofetil.
  • the other compound is tissue plasminogen activator (t-PA).
  • the other compound inhibits or reduces the expression or activity of one or more of:
  • kidney injury molecule 1 KIM-1
  • neutrophil gelatinase-associated lipocalin (ii) neutrophil gelatinase-associated lipocalin (NGAL);
  • TNF ⁇ tumor necrosis factor alpha
  • xii monocyte chemoattractant protein 1 (MCP-1).
  • the other compound is hydrogen sulfide. In some examples, the other compound is cyclosporine. In some examples, the other compound is TRO040303, as described in Le Lamer et al., J Transl Med (2014). In some examples, the other compound is superoxide dismutase. In some examples, the other compound is a cannabinoid or a synthetic analog thereof.
  • the other compound is one that is commonly used in transplantation surgery.
  • the compound that inhibits G-CSF signaling is administered simultaneously with the other compound. In one example, the compound that inhibits G-CSF signaling is administered before the other compound. In one example, the compound that inhibits G-CSF signaling is administered after the other compound.
  • the compound that inhibits G-CSF signaling is administered in combination with a cell.
  • the cell is a stem cell, such as a mesenchymal stem cell.
  • the compound that inhibits G-CSF signaling is administered in combination with a gene therapy.
  • Suitable dosages of compounds of the present disclosure will vary depending on the specific compound, the condition to be treated and/or the subject being treated. It is within the ability of a skilled physician to determine a suitable dosage, e.g., by commencing with a sub-optimal dosage and incrementally modifying the dosage to determine an optimal or useful dosage. Alternatively, to determine an appropriate dosage for treatment/prophylaxis, data from the cell culture assays or animal studies are used, wherein a suitable dose is within a range of circulating concentrations that include the ED 50 of the active compound with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. A therapeutically/prophylactically effective dose can be estimated initially from cell culture assays.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
  • the compound that inhibits G-CSF signaling is administered systemically. In some examples, the compound that inhibits G-CSF signaling is administered locally.
  • the compound that inhibits G-CSF signaling is not necessarily directly administered to the subject.
  • the compound may be administered to an organ donor or to an organ (e.g. a harvested organ) prior to transplantation to the subject, which thereby reduces the effects of the resulting ischemia-reperfusion injury in the subject after transplantation.
  • ischemia-reperfusion injury in a subject can be treated without directly administering to the subject the compound that inhibits G-CSF signaling.
  • the compound that inhibits G-CSF signaling is administered to the subject.
  • the subject is an organ transplant recipient.
  • a method of the present disclosure comprises administering a prophylactically or therapeutically effective amount of a compound described herein.
  • terapéuticaally effective amount is the quantity which, when administered, improves the prognosis and/or state of the subject and/or that reduces or inhibits one or more symptoms of a clinical condition described herein to a level that is below that observed and accepted as clinically diagnostic or clinically characteristic of that condition.
  • the amount to be administered will depend on the particular characteristics of the condition to be treated, the type and stage of condition being treated, the mode of administration, and the characteristics of the subject, such as general health, other diseases, age, sex, genotype, and body weight. A person skilled in the art will be able to determine appropriate dosages depending on these and other factors.
  • this term is not to be construed to limit the present disclosure to a specific quantity, e.g., weight or amount of compound, rather the present disclosure encompasses any amount of the compound that inhibits G-CSF signaling sufficient to achieve the stated result in a subject. In one example, a therapeutically effective amount of the compound that inhibits G-CSF signaling does not induce neutropenia.
  • prophylactically effective amount shall be taken to mean a sufficient quantity of a compound to prevent or inhibit or delay the onset of one or more detectable symptoms of a clinical condition.
  • the skilled artisan will be aware that such an amount will vary depending on, for example, the specific compound administered and/or the particular subject and/or the type or severity or level of condition and/or predisposition (genetic or otherwise) to the condition. Accordingly, this term is not to be construed to limit the present disclosure to a specific quantity, e.g., weight or amount of compound, rather the present disclosure encompasses any amount of the compound that inhibits G-CSF signaling sufficient to achieve the stated result in a subject. In one example, a prophylactically effective amount of the compound that inhibits G-CSF signaling does not induce neutropenia.
  • normal dosage amounts may vary from about 10 ng/kg up to about 100 mg/kg of an individual's body weight or more per day. Exemplary dosages and ranges thereof are described herein.
  • the treatment can be sustained until a desired suppression of symptoms is achieved.
  • the compound that inhibits G-CSF signaling is administered at an initial (or loading) dose of between about 0.1 mg/kg to about 30 mg/kg, such as from about 1 mg/kg to about 10 mg/kg, or about 2 mg/kg to 8 mg/kg, or about 4 mg/kg to 6 mg/kg.
  • the compound that inhibits G-CSF signaling can then be administered at a lower maintenance dose of between about 0.01 mg/kg to about 5 mg/kg, such as from about 0.05 mg/kg to about 1 mg/kg, for example, from about 0.1 mg/kg to about 1 mg/kg, such as about 0.1 mg/kg or 0.5 mg/kg or 1 mg/kg or 2 mg/kg or 3 mg/kg or 4 mg/kg or 5 mg/kg.
  • the maintenance doses may be administered every 7-30 days, such as, every 10-15 days, for example, every 10 or 11 or 12 or 13 or 14 or 15 days.
  • a maintenance dose can be used in order to maintain a therapeutically effective level of the compound in the blood of the subject for a length of time, for example after organ transplantation surgery.
  • the compound that inhibits G-CSF signaling is administered at a dose of between about 0.1 mg/kg to about 1 mg/kg. In some examples, the compound that inhibits G-CSF signaling is administered at a dose of between about 0.4 mg/kg to about 0.5 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.1 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.2 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.3 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.4 mg/kg.
  • the compound that inhibits G-CSF signaling is administered at a dose of about 0.5 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.6 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.7 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 0.8 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of about 1 mg/kg.
  • the compound that inhibits G-CSF signaling is administered at a dose of between about 0.01 mg/kg to about 50 mg/kg, such as between about 0.1 mg/kg to about 40 mg/kg, for example, between about 2 mg/kg to about 30 mg/kg, for example, between about 5 mg/kg to about 25 mg/kg.
  • the compound that inhibits G-CSF signaling is administered at a dose of between about 2 mg/kg to about 8 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of between about 4 mg/kg to about 6 mg/kg.
  • the compound that inhibits G-CSF signaling is administered at a dose of between about 10 mg/kg to about 40 mg/kg. In one example, the compound that inhibits G-CSF signaling is administered at a dose of between about 20 mg/kg to about 30 mg/kg.
  • the compound that inhibits G-CSF signaling is administered at a dose of about 5 mg/kg. In some examples the compound that inhibits G-CSF signaling is administered at a dose of about 10 mg/kg. In some examples the compound that inhibits G-CSF signaling is administered at a dose of about 25 mg/kg.
  • the compound that inhibits G-CSF signaling is administered without a higher loading dose or a lower maintenance dose.
  • the compound that inhibits G-CSF signaling is administered as a single dose.
  • numerous doses are administered, e.g., every 7-30 days, such as, every 10-22 days, for example, every 10-15 days, for example, every 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 days.
  • the compound that inhibits G-CSF signaling is administered every 7 days or every 14 days or every 21 days.
  • the mammal is administered the compound that inhibits G-CSF signaling on no more than 7 consecutive days or 6 consecutive days or 5 consecutive days or 4 consecutive days.
  • multiple doses in a week may be administered.
  • increasing doses may be administered.
  • the initial (or loading) dose may be split over numerous days in one week or over numerous consecutive days.
  • Administration of a compound according to the methods of the present disclosure can be continuous or intermittent, depending, for example, on the recipient's physiological condition, whether the purpose of the administration is therapeutic or prophylactic, and other factors known to skilled practitioners.
  • the administration of a compound may be essentially continuous over a preselected period of time or may be in a series of spaced doses, e.g., either during or after development of a condition.
  • the compound that inhibits G-CSF signaling is administered before an ischemia.
  • the compound that inhibits G-CSF signaling is administered between between 0 days (e.g., immediately prior to ischemia) to 7 days before ischemia.
  • the compound that inhibits G-CSF signaling is administered between 0 days and 6 days or 5 days or 4 days before ischemia.
  • the compound that inhibits G-CSF signaling is administered between 0 and 48 hours before the ischemia.
  • the compound that inhibits G-CSF signaling is administered between 12 and 36 hours before the ischemia.
  • the compound that inhibits G-CSF signaling is administered about 24 hours before the ischemia.
  • the compound that inhibits G-CSF signaling is administered after the ischemia. In some examples, the compound that inhibits G-CSF signaling is administered before and after the ischemia. In some examples, the compound that inhibits G-CSF signaling is administered during the ischemia, for example during tissue or organ transplantation surgery.
  • the compound that inhibits G-CSF signaling is administered at least 1 hour before the ischemia (e.g., out to 7 days or longer before ischemia). In some examples, the compound that inhibits G-CSF signaling is administered at least 2 or at least 4 or at least 6 or at least 8 or at least 10 or at least 12 hours or at least 14 hours or at least 16 hours or at least 18 hours or at least 20 hours or at least 22 hours or at least 24 hours before the ischemia.
  • the compound that inhibits G-CSF signaling is administered before reperfusion.
  • the compound that inhibits G-CSF signaling is administered between between 0 days (e.g., immediately reperfusion) to 7 days before reperfusion.
  • the compound that inhibits G-CSF signaling is administered between 0 days and 6 days or 5 days or 4 days before reperfusion.
  • the compound that inhibits G-CSF signaling is administered between 0 and 48 hours before reperfusion.
  • the compound that inhibits G-CSF signaling is administered between 12 and 36 hours before reperfusion.
  • the compound that inhibits G-CSF signaling is administered about 24 hours before reperfusion.
  • the compound that inhibits G-CSF signaling is administered after reperfusion.
  • the compound that inhibits G-CSF signaling is administered before and after reperfusion.
  • the compound that inhibits G-CSF signaling is administered at least 1 hour before reperfusion. In some examples, the compound that inhibits G-CSF signaling is administered at least 2 or at least 4 or at least 6 or at least 8 or at least 10 or at least 12 hours or at least 14 hours or at least 16 hours or at least 18 hours or at least 20 hours or at least 22 hours or at least 24 hours (e.g., out to 7 days or longer) before reperfusion.
  • the compound that inhibits G-CSF signaling can be administered either before, during or after transplantation.
  • the compound that inhibits G-CSF signaling is administered before transplantation.
  • the compound that inhibits G-CSF signaling is administered during transplantation, for example prior to clamp release at which time blood flow is restored to the transplanted organ.
  • the compound that inhibits G-CSF signaling is administered after transplantation.
  • the compound that inhibits G-CSF signaling is administered to the subject, wherein the subject is a tissue or organ transplantation recipient. In some examples, the compound that inhibits G-CSF signaling is administered to the tissue or organ transplantation recipient before reperfusion. In one example, the compound that inhibits G-CSF signaling is administered to the tissue or organ transplantation recipient after reperfusion.
  • the compound that inhibits G-CSF signaling is administered to the tissue or organ transplantation donor prior to tissue or organ harvest.
  • the tissue or organ transplantation donor is a living donor.
  • the donor is a deceased donor.
  • Deceased donors can be classified into several groups depending on the quality of the organ and/or the sequence and mechanisms of cessation of circulatory and respiratory functions. Classification of deceased donors is described in Panduranga & Akinlolu (Clin J Am Soc Nephrol 4: 1827-1831,200).
  • the donor is a donation after brain death (DBD) donor, also referred to as a ‘brain-dead’ donor.
  • DBD donor is a donor who has had primary brain death but whose circulatory system remains functional, either naturally or by medical measures (e.g., mechanical ventilation, drugs, intra-aortic balloon pump, or extracorporeal machine oxygenation device).
  • the compound that inhibits G-CSF signaling is administered to the DBD donor before organ harvest and is distributed to the potential transplant organs by blood circulation.
  • the donor is a donation after circulatory death (DCD) donor, also referred to as a ‘donation after cardiac death’ donor or a ‘non-heart-beating donor’.
  • DCD donor is a donor whose circulatory function had been lost (e.g., heart death) prior to organ harvest.
  • artificial circulation such as by heart-lung bypass instruments may be needed to deliver the compound administered to the DCD donor to the organ(s) contemplated for harvest and transplant.
  • DCD donors can be further classified into further subgroups.
  • the DCD donor is a controlled DCD (cDCD) donor.
  • cDCD donor is a donor whose life support will be withdrawn and whose family has given written consent for organ donation in the controlled environment of the operating room.
  • the DCD donor is an uncontrolled DCD (uDCD) donor.
  • uDCD donor is a donor, for example, who expires in the emergency room or elsewhere in the hospital before consent for organ donation is obtained and catheters are placed in the femoral vessels and peritoneum to cool organs until consent can be obtained.
  • a uDCD donor is also a donor who has consented for organ donation but suffers a cardiac arrest requiring CPR during procurement of the organs.
  • the donor is an expanded-criteria donor (ECD).
  • ECD is a donor who, at the time of death, is aged 60 or older or who is aged 50 to 59 years and has any two the following three criteria: (1) cause of death is cerebrovascular accident; (2) preexisting history of systemic hypertension; and (3) terminal serum creatinine greater than 1.5 mg/dL.
  • the donor is a standard-criteria donor (SCD).
  • SCD is a donor who is less than 50 years in age. Generally, all deceased donors for whom donation occurred after brain death and who do not meet any of the criteria for an ECD (see above) are considered an SCD.
  • the compound that inhibits G-CSF signaling is administered shortly following determination of brain death, or as soon following brain death as is feasible given legal, ethical, and patient considerations.
  • the attendant physician or transplant surgeon will recognise a multiplicity of factors that influence the timing of organ harvest from a suitable donor and transplant of harvested organs into a suitable recipient.
  • the compound that inhibits G-CSF signaling is administered to the donor at any time between the occurrence of brain death and removal of an organ intended for transplant.
  • the compound that inhibits G-CSF signaling is administered to a harvested tissue or organ ex vivo, prior to tissue or organ transplantation.
  • the harvested tissue or organ can be perfused or infused with a solution comprising the compound that inhibits G-CSF signaling prior to transplantation.
  • kits containing compounds useful for the treatment of ischemia-reperfusion injury as described above are provided.
  • the kit comprises (a) a container comprising a compound that inhibits G-CSF signaling as described herein, optionally in a pharmaceutically acceptable carrier or diluent; and (b) a package insert with instructions for reducing an effect of ischemia-reperfusion injury in a subject.
  • the package insert is on or associated with the container.
  • Suitable containers include, for example, bottles, vials, syringes, etc.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds or contains a composition that is effective for treating the ischemia-reperfusion injury and may have a sterile access port (for example, the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • At least one active agent in the composition is the compound that inhibits G-CSF signaling that inhibits G-CSF signaling.
  • the label or package insert indicates that the composition is used for treating a subject eligible for treatment, e.g., an organ transplant recipient, with specific guidance regarding dosing amounts and intervals of compound and any other medicament being provided.
  • the kit may further comprise an additional container comprising a pharmaceutically acceptable diluent buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and/or dextrose solution.
  • BWFI bacteriostatic water for injection
  • phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and/or dextrose solution.
  • BWFI bacteriostatic water for injection
  • the kit may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
  • the present disclosure includes the following non-limiting Examples.
  • mice Male C57BL/6 wild type mice aged 10 to 12 weeks were obtained from the Animal Resource Centre, Perth, Australia. Mice were housed in an approved animal facility within St. Vincent's Hospital Melbourne, and all experiments involving animals were approved by the Animal Ethics Committee of St. Vincent's Hospital Melbourne.
  • mice were anesthetized by i.p. administration of ketamine 85 mg/kg and xylazine 15 mg/kg. After the mice were anesthetized, they were placed on a heating pad to maintain their core body temperature at 37° C. during the surgery. A midline abdominal incision was made and the renal pedicles were bluntly dissected. After right nephrectomy, a microvascular clamp (Roboz, Rockville, Md.) was placed on the left renal pedicle for 22 min. while the animal was kept at 37° C. in an incubator and well hydrated. The clamp was removed after ischemia and the kidney observed to confirm complete reperfusion. The surgical wounds were then sutured in two layers with 5-0 silk.
  • ketamine 85 mg/kg and xylazine 15 mg/kg After the mice were anesthetized, they were placed on a heating pad to maintain their core body temperature at 37° C. during the surgery. A midline abdominal incision was made and the renal pedicles were bluntly diss
  • mice Warm normal saline (100 ml/kg) was instilled into the peritoneal cavity during the procedure. The mice were allowed to recover for 2 h under a heating lamp and then kept on a heating pad. The mice were euthanized 24 h after reperfusion, and blood and kidney samples obtained. Sham-operated mice had right nephrectomy only, without IR.
  • Anti-mouse G-CSFR (Ch5E2-VR81-mIgG1x), isotype control (BM4, mouse isotype IgG1x) or anti-C5 antibody (muBB5.1-mIgG1x) (Rother R, et al. Nat Biotechnol. 2007) were injected at 100 ⁇ g/mouse in 0.2 ml PBS intraperitoneally 24 h before starting ischemia.
  • anti-mouse G-CSFR (Ch5E2-VR81-mIgG1x) was injected at 200 ⁇ g/mouse or 500 ⁇ g/mouse in 0.2 ml PBS intraperitoneally 24 h before ischemia.
  • VR81 is a mouse monoclonal IgG1 ⁇ antibody produced against the extracellular domain of murine G-CSFR and blocks G-CSF binding to G-CSFR as described (Campbell et al. Journal of Immunology, 197(11) (2016) 4392-4402). In this regard, VR81 is mouse surrogate antibody for C1.2 and C1.2G described herein and in WO2012171057.
  • Renal function was assessed by measurement of serum creatinine and serum or plasma urea at 24 hours after reperfusion. Creatinine was measured using a kinetic colorimetric assay based on the Jaffé method, analyzed on a Roche COBAS Integra 400 Plus analyzer. Cell Biolabs' Urea Assay Kit is based on the Berthelot reaction. Urea is first degraded into ammonia and carbon dioxide, which further reacts with an alkaline developer to produce a blue-green colored product that can be measured with a standard spectrophotometric plate reader at an optical density between 580-630 nm.
  • the activation of complement in mouse plasma was measured using a mouse C5a DuoSet ELISA kit (DY2150; R&D Systems, Minneapolis, Minn.) according to the manufacturer's instructions. Deposition of the C5b-9 in kidney sections was measured by immunofluorescence (see below).
  • Snap-frozen biopsy samples were cut into 5-mm-thick sections, air dried, and either processed immediately or stored at 280′C until further analysis. After fixation with acetone and hydration, the sections were stained using: rabbit anti-mouse C9 Alexa 488 (Bioss Antibodies, Woburn, Mass.), rat anti-mouse Ly-6GFITC (Hycult Bio-tech), rat anti-mouse F4/80 FITC (Bio-Rad, Raleigh, N.C.), or FITC-conjugated isotype-matched control Ab: rat IgG1 (BD Biosciences, San Diego, Calif.). The slides were analyzed using a fluorescence/confocal microscope (Nikon AIR). Quantification of fluorescence intensity as raw integrated density was performed using ImageJ software, version 10.2 (National Institutes of Health) on unmanipulated TIFF images.
  • RNA from frozen mouse kidneys was isolated using the PureLink RNA mini kit (Life Technologies, Carlsbad, Calif.) according to the manufacturer's instructions. Total RNA quality and quantity were determined using the NanoDrop spectrophotometer (NanoDrop Technologies, Oxfordshire, UK). First-strand complementary DNA synthe-sis was performed by incubating 1.0 g total RNA in a 50- ⁇ L reaction mix containing 0.5 ⁇ g Oligo (dT) primers and 1 g random primers (both from Invitrogen, Carlsbad, Calif.) at 70° C. for 10 minutes.
  • dT Oligo
  • a 1 ⁇ 8 piece of kidney was cut with a scalpel into smaller pieces, which were digested in 500 ul Collagenase Type I (10 ug/ml in PBS 2 mM EDTA) under shaking conditions at 37° C. for 30 min.
  • Cells were isolated by passing the tissue digest through a 70 um strainer. Red blood cells were lysed using RCRB buffer (156 mM NH4Cl, 11.9 mM NaHCO 3 , 0.097 mM EDTA, pH7.3). Cells were finally resuspended in PBS 2 mM EDTA.
  • Peripheral blood was collected into EDTA-coated tubes, red blood cells were lysed using RCRB buffer (as above) and cells were resuspended in PBS 2 mM EDTA.
  • FcR block anti-mouse CD16/32 (93; Biolegend) was added to reduce non-specific binding and Fixable Live/Dead Yellow (Thermo Fisher Scientific) was used to exclude dead cells. Samples were fixed overnight using BD Cytofix Fixation buffer (BD Biosciences) and then analysed on a BD Fortessa, using FlowJo software.
  • Kidney damage in the renal cortex was assessed in the warm renal IRI model in in mice treated with 100 ⁇ g of an anti-G-CSFR antibody (VR81).
  • the degree of tubular necrosis was graded and expressed as a Tubular Injury (TI) score in accordance with Table 3.
  • TI was determined without knowledge of the treatment group by two independent operators assessing the percentage of renal tubular injury involvement (necrosis, cast formation, cell swelling, and dilatation).
  • Example 5 KIM-1, NGAL, IL-6, IL-8R ⁇ /CXCR2, MCP-1/CCL2, CXCL1, MIP-2/CXCL2, ICAM-1, and C5aR mRNAexpression in Renal Tissue—Warm Renal IRI Model
  • mice were injected with 100 ⁇ g/mouse of the anti-G-CSFR antibody VR81 24 h before ischemia/reperfusion injury was induced in the warm renal IRI model.
  • RNA was isolated from the kidneys and subjected to qRT-PCR as described in Example 1.
  • the mRNA transcript levels of KIM-1, NGAL, IL-6, IL-8R ⁇ /CXCR2, MCP-1/CCL2, ICAM-1, C5aR, IL-1 ⁇ , TNF ⁇ , CXCL1, MIP-2/CXCL2 and E-selectin were determined. Transcript levels of these genes were quantified and normalised against GAPDH.
  • the initial results were confirmed using a dose of 200 ⁇ g/mouse or 500 ⁇ g/mouse of VR81.
  • Table 4 and FIG. 7 shows that VR81 treatment at a dosage of 500 ⁇ g/mouse significantly reduced expression of KIM-1, NGAL, IL-6, IL-8RP/CXCR2, ICAM-1, C5aR, MIP-2/CXCL2, MCP-1/CCL2, and CXCL1 compared to treatment with the isotype control antibody.
  • Kidney neutrophils (CD11b + Gr1 + ) and leukocytes (CD11b ⁇ Gr1 ⁇ CD45.2 + ) were enumerated by tissue digestion and flow cytometry according to the methods described in Example 1. The percentage of live cells was determined based on PI staining of total cell populations.
  • anti-mouse G-CSFR antibody VR81 was injected 24 h before ischemia-reperfusion injury at a dose of 200 ⁇ g/mouse or 500 ⁇ g/mouse. Mice treated with 500 ⁇ g/mouse of the isotype control antibody served as controls.
  • mice treated with 500 g of VR81 There was a significant reduction in serum creatinine and serum urea levels in mice treated with 500 g of VR81, but not mice treated with 200 g of VR81, or 500 ⁇ g of the isotype control antibody as shown in Table 5 and FIGS. 11 and 12 .
  • Example 8 Inhibition of G-CSF Signaling Reduces Complement C5 Activation and C5b-9 Deposition in a Warm Renal IRI Model
  • Example 9 Administration of an Inhibitor of G-CSF Signaling 1 h Before Ischemia Reduces Frequency of Neutrophils in Kidney and Blood in a Warm Renal IRI Model

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
US16/768,159 2017-11-29 2018-11-29 Method of treating or preventing ischemia-reperfusion injury Abandoned US20210179721A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017904822A AU2017904822A0 (en) 2017-11-29 Method of treating or preventing ischemia-reperfusion injury
AU2017904822 2017-11-29
PCT/AU2018/051272 WO2019104385A1 (fr) 2017-11-29 2018-11-29 Procédé de traitement ou de prévention d'une lésion liée à l'ischémie-reperfusion

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2018/051272 A-371-Of-International WO2019104385A1 (fr) 2017-11-29 2018-11-29 Procédé de traitement ou de prévention d'une lésion liée à l'ischémie-reperfusion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/152,439 Continuation US20230279129A1 (en) 2017-11-29 2023-01-10 Method of treating or preventing ischemia-reperfusion injury

Publications (1)

Publication Number Publication Date
US20210179721A1 true US20210179721A1 (en) 2021-06-17

Family

ID=66663689

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/768,159 Abandoned US20210179721A1 (en) 2017-11-29 2018-11-29 Method of treating or preventing ischemia-reperfusion injury
US18/152,439 Pending US20230279129A1 (en) 2017-11-29 2023-01-10 Method of treating or preventing ischemia-reperfusion injury

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/152,439 Pending US20230279129A1 (en) 2017-11-29 2023-01-10 Method of treating or preventing ischemia-reperfusion injury

Country Status (12)

Country Link
US (2) US20210179721A1 (fr)
EP (1) EP3717011B1 (fr)
JP (1) JP7465210B2 (fr)
KR (1) KR102684627B1 (fr)
CN (1) CN111417406A (fr)
AU (1) AU2018377856A1 (fr)
BR (1) BR112020010514A2 (fr)
CA (1) CA3081770A1 (fr)
DK (1) DK3717011T5 (fr)
ES (1) ES2939461T3 (fr)
PL (1) PL3717011T3 (fr)
WO (1) WO2019104385A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828482T3 (es) 2011-06-13 2021-05-26 Csl Ltd Anticuerpos contra el g-csfr y su uso
WO2020113270A1 (fr) * 2018-12-04 2020-06-11 CSL Innovation Pty Ltd Méthode de traitement d'affections neutrophiles

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1994004678A1 (fr) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulines exemptes de chaines legeres
EP1550729B1 (fr) 1992-09-25 2009-05-27 Avipep Pty Limited Polypeptides se fixant à une cible comprenant un domaine de type immunoglobuline (IG-like) VL fusioné à une domaine de type immunoglobuline (IG-like) VH
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
CA2229043C (fr) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Banques de proteines/(poly)peptides
ATE374248T1 (de) 1996-06-27 2007-10-15 Vlaams Interuniv Inst Biotech Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
WO1999057134A1 (fr) 1998-05-06 1999-11-11 Genentech, Inc. Purification de proteines par chromatographie par echange d'ions
EP1051432B1 (fr) 1998-12-08 2007-01-24 Biovation Limited Modification de l'immunogenicite de proteines
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2335861T3 (es) 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
JP2006526414A (ja) 2003-06-02 2006-11-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 脱免疫化抗ｃｄ３抗体
US7993650B2 (en) 2003-07-04 2011-08-09 Affibody Ab Polypeptides having binding affinity for HER2
WO2005019255A1 (fr) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteines de la lipocaline lacrymale
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US7977071B2 (en) 2004-06-02 2011-07-12 Adalta Pty Ltd. Binding moieties based on shark ignar domains
CA2580981C (fr) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Anticorps igg4 humains stabilises
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
EP2267030A1 (fr) 2005-08-25 2010-12-29 Repair Technologies, Inc. Dispositifs, compositions et méthodes de protection et de réparation de cellules et de tissus
PL2056858T3 (pl) 2006-08-11 2015-01-30 Csl Ltd Leczenie stanów chorobowych płuc
US20080199426A1 (en) 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
KR20110104032A (ko) 2008-12-19 2011-09-21 마크로제닉스, 인크. 공유결합형 디아바디 및 이의 용도
BRPI1006998A2 (pt) 2009-01-23 2015-08-25 Biogen Idec Inc Polipeptídeos fc estabilizados com função efetora reduzida e métodos de uso
CA2776241A1 (fr) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Variants d'albumine
CN104610454A (zh) 2010-02-16 2015-05-13 米迪缪尼有限公司 Hsa相关组合物及使用方法
EP2367000A1 (fr) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin Analyse à haut rendement des répertoires de récepteur de lymphocyte T
JP2014510518A (ja) 2011-02-15 2014-05-01 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
ES2828482T3 (es) 2011-06-13 2021-05-26 Csl Ltd Anticuerpos contra el g-csfr y su uso
EP2780364A2 (fr) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Protéines ayant une demi-vie et d'autres propriétés améliorées
US9050305B2 (en) 2012-03-29 2015-06-09 Chs Pharma, Inc. Treatment for ischemic stroke
US20140128326A1 (en) 2012-11-08 2014-05-08 Novozymes Biopharma Dk A/S Albumin variants
WO2014179657A1 (fr) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Variantes d'albumine se liant à fcrn
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
KR102560025B1 (ko) * 2014-11-17 2023-07-26 씨에스엘 리미티드 뇌졸중의 치료 또는 예방 방법
US20190119369A1 (en) * 2016-04-21 2019-04-25 Csl Limited Method of treating or preventing liver conditions

Also Published As

Publication number Publication date
DK3717011T5 (da) 2024-08-26
JP2021504382A (ja) 2021-02-15
CN111417406A (zh) 2020-07-14
ES2939461T3 (es) 2023-04-24
PL3717011T3 (pl) 2023-03-27
AU2018377856A1 (en) 2020-05-21
KR20200093562A (ko) 2020-08-05
US20230279129A1 (en) 2023-09-07
EP3717011A1 (fr) 2020-10-07
JP7465210B2 (ja) 2024-04-10
DK3717011T3 (da) 2023-01-09
EP3717011A4 (fr) 2021-09-08
EP3717011B1 (fr) 2022-12-07
KR102684627B1 (ko) 2024-07-15
WO2019104385A1 (fr) 2019-06-06
BR112020010514A2 (pt) 2020-11-24
CA3081770A1 (fr) 2019-06-06

Similar Documents

Publication Publication Date Title
US11618787B2 (en) Methods of treating high risk multiple myeloma
US20230279129A1 (en) Method of treating or preventing ischemia-reperfusion injury
US10961304B2 (en) Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B)
US20210009677A1 (en) Method of treating asthma
EP3074038B1 (fr) Méthode de traitement de la néphropathie diabétique
JP7317827B2 (ja) 腎線維症および／または慢性腎臓疾患の治療におけるＦＸＩＩａインヒビターの使用
WO2021243424A1 (fr) Procédé de traitement ou de prévention du syndrome de détresse respiratoire aiguë
US20230416381A1 (en) Methods for treating or preventing acute respiratory distress syndrome
US20230406943A1 (en) Methods for treating inflammatory skin conditions
CN117015398A (zh) 治疗炎性皮肤病症的方法
AU2021408085A9 (en) Methods for treating or preventing acute respiratory distress syndrome
BR112017010336B1 (pt) Uso de um composto que inibe a sinalização de vegf-b

Legal Events

Date Code Title Description
AS Assignment

Owner name: CSL LIMITED, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VIKSTROM, INGELA;BAZ MORELLI, ADRIANA;PEARSE, MARTIN;REEL/FRAME:052785/0250

Effective date: 20181126

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION